Alirocumab vs Inclisiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Alirocumab · Praluent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Weak signal

NCT01507831 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 trial (ODYSSEY LONG TERM) gave alirocumab 150 mg or placebo every 2 weeks for 78 weeks, on top of maximum tolerated statins, to 2,341 patients at high cardiovascular risk. Its registered primary objective and primary outcome are long-term safety and tolerability, which have no formal efficacy test, so the registered primary has no met or missed result. The published paper reports the efficacy end point it pre-specified: LDL cholesterol fell 62 percentage points more with alirocumab than with placebo at week 24 (P<0.001). Sources: CT.gov posted results and the peer-reviewed paper (Robinson et al., N Engl J Med 2015). Its registered primary outcome on ClinicalTrials.gov is "Percentage of Participants Who Experienced Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07477704 (registry estimate)

Reported efficacy

DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7) (met)

Result source: NCT03510884

Inclisiran · Leqvio

Marketed by Novartis and partners

Phase 3 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT03397121 · Phase 3 · completed

The trial randomly assigned 482 participants to double-blind inclisiran or placebo, with 242 receiving inclisiran and 240 receiving placebo. Both primary LDL-C comparisons were statistically significant in favor of inclisiran, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical outcome, supporting a moderate evidence grade.

Next expected readout: November 2026 · NCT06501443 (registry estimate)

Reported efficacy

Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78) (met)

Result source: NCT04652726

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlirocumabInclisiran
LDL-C, % change-52.7% vs -0.3%−52.4 vs placebo300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144NCT01926782
165 other results
  • -58.8% vs -0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · primary NCT01926782
  • -45.7% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · primary NCT01617655
  • -48.2% vs -2.3% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · primary NCT01644175
  • -48.8% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · primary NCT01623115
  • -48.7% vs 2.8% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · primary NCT01709500
  • -48.2% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · primary NCT02585778
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · primary NCT03156621
  • -43.8% vs -4.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · primary NCT02584504
  • -70.1% vs -4.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · primary NCT02584504
  • -51.7% vs 4.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · primary NCT02023879
  • -50.2% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · primary NCT01926782
  • -51.6% vs -0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · primary NCT01926782
  • -51.8% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · primary NCT02585778
  • -57.1% vs 6.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · primary NCT02289963
  • -62.5% vs 1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · primary NCT02107898
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · primary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · primary NCT03510884
  • -50.6% vs -20.7% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · primary NCT01644188
  • -56% vs -20.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · primary NCT02715726
  • -47.2% vs -15.6% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · primary NCT01644474
  • -45% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · primary NCT01709513
  • -50.6% vs -15.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · primary NCT01730053
  • -36.3% vs -15.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · primary NCT01730053
  • -44.1% vs -5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · primary NCT01730040
  • -54% vs -5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · primary NCT01730040
  • -55.8% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9462 · Phase 3 · secondary NCT01663402
  • -58.3% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9451 · Phase 3 · secondary NCT01663402
  • -45.7% vs 8% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9462 · Phase 3 · secondary NCT01663402
  • -52.8% vs 8.2% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9451 · Phase 3 · secondary NCT01663402
  • -23.5% vs 16.4% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9462 · Phase 3 · secondary NCT01663402
  • -40.1% vs 14.6% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9451 · Phase 3 · secondary NCT01663402
  • -63.3% vs 1.5% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -64.2% vs 1.4% 150 mg Q2W · wk 12 · n 1523 · Phase 3 · secondary NCT01507831
  • -61% vs 0.8% 150 mg Q2W · wk 24 · n 1530 · Phase 3 · secondary NCT01507831
  • -62.8% vs 0.7% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -57.8% vs 3.5% 150 mg Q2W · wk 24 · n 1278 · Phase 3 · secondary NCT01507831
  • -56.8% vs 4.4% 150 mg Q2W · wk 52 · n 1530 · Phase 3 · secondary NCT01507831
  • -59.9% vs 4.6% 150 mg Q2W · wk 52 · n 1523 · Phase 3 · secondary NCT01507831
  • -52.4% vs 3.6% 150 mg Q2W · wk 78 · n 1530 · Phase 3 · secondary NCT01507831
  • -58% vs 3.9% 150 mg Q2W · wk 78 · n 1523 · Phase 3 · secondary NCT01507831
  • -58.4% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -55.3% vs 1.1% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -60% vs -0.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT01926782
  • -58% vs 1.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 302 · Phase 3 · secondary NCT01926782
  • -59.4% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -62.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -43.5% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -43.8% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -44.2% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -49.4% vs 2.7% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -47.1% vs 9% 75 mg/Up to 150 mg Q2W · wk 52 · n 322 · Phase 3 · secondary NCT01623115
  • -40.3% vs 11.5% 75 mg/Up to 150 mg Q2W · wk 78 · n 322 · Phase 3 · secondary NCT01623115
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.3% vs 1.1% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -47.6% vs 1.7% 75/150 mg Q2W · wk 12 · n 204 · Phase 3 · secondary NCT01644175
  • -45.5% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -50.7% vs -0.8% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -43.9% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 321 · Phase 3 · secondary NCT01623115
  • -55.1% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -50.3% vs 8.4% 75 mg/up to 150 mg · wk 52 · n 166 · Phase 3 · secondary NCT01709500
  • -43.7% vs 14% 75 mg/Up to 150 mg Q2W · wk 78 · n 321 · Phase 3 · secondary NCT01623115
  • -42.1% vs -3% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42% vs -2.9% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42.5% vs 0.5% 75/150 mg Q2W · wk 52 · n 205 · Phase 3 · secondary NCT01644175
  • -49.3% vs 8.8% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -48.1% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 52 · n 321 · Phase 3 · secondary NCT01623115
  • -53.7% vs 1.6% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -43.4% vs -2.8% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -70.1% vs -2.8% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54.2% vs -3.7% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -3.7% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54% vs -2.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -2.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -41.7% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -44.8% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 57 · Phase 3 · secondary NCT02023879
  • -42.3% vs 4% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -54.6% vs 5.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -40.9% vs -0.2% 150 mg Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -52.3% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · n 58 · Phase 3 · secondary NCT02023879
  • -55% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · n 57 · Phase 3 · secondary NCT02023879
  • -51.8% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -45.3% vs 1.1% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -53.9% vs -0.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -47.3% vs 1.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -50.8% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -51.5% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -48.8% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 284 · Phase 3 · secondary NCT02585778
  • -44.8% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 275 · Phase 3 · secondary NCT02585778
  • -55.3% vs 5.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -50.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 284 · Phase 3 · secondary NCT02585778
  • -43.3% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 277 · Phase 3 · secondary NCT02585778
  • -49.4% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 49 · Phase 3 · secondary NCT02585778
  • -64.2% vs -2.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -64.8% vs -2.8% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -63.7% vs 1.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -46.7% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 45 · Phase 3 · secondary NCT02585778
  • -57.9% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -58.4% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -53.8% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -49.4% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -60.2% vs 6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -62.5% vs -3.6% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -64.6% vs -3.4% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -53.6% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.1% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.6% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -37.9% vs 1.2% 150 Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -51.2% vs -21.8% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -52.4% vs -22.7% 75 /up to 150 mg Q2W · wk 12 · n 464 · Phase 3 · secondary NCT01644188
  • -52.4% vs -21.8% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -49.5% vs -18.3% 75 /up to 150 mg Q2W · wk 52 · n 467 · Phase 3 · secondary NCT01644188
  • -51.8% vs -19.7% 75 /up to 150 mg Q2W · wk 52 · n 464 · Phase 3 · secondary NCT01644188
  • -44.2% vs -15.2% 75 /up to 150 mg Q2W · wk 104 · n 467 · Phase 3 · secondary NCT01644188
  • -48.9% vs -17% 75 /up to 150 mg Q2W · wk 104 · n 464 · Phase 3 · secondary NCT01644188
  • -57.1% vs -22.2% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -58.1% vs -22.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 401 · Phase 3 · secondary NCT02715726
  • -58.7% vs -21.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -48.1% vs -19.6% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -47% vs -15.6% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -51.2% vs -18% 75 mg/ up to 150 mg · wk 12 · n 123 · Phase 3 · secondary NCT01709513
  • -52.2% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -47.3% vs -15.2% 75 mg/ up to 150 mg · wk 24 · n 112 · Phase 3 · secondary NCT01709513
  • -49.6% vs -22.1% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -32.3% vs -22.1% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -52.6% vs -22.9% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -35.1% vs -22.9% 75 mg/up to 150 mg + 20 mg · wk 12 · n 51 · Phase 3 · secondary NCT01730053
  • -48.4% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -50.5% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -53.7% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 52 · Phase 3 · secondary NCT01730040
  • -50.9% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -53.5% vs -17% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -41.5% vs -17% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -48.6% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -57.8% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -66.2% vs -51.2% wk 4 · n 31 · Phase 3 · secondary NCT03415178
  • -73% vs 2% wk 2 · n 10 · Phase 4 · primary NCT02938949
  • -49.6% vs 0.6% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -54.2% vs 3% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -51.4% vs 2.8% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -50.4% vs 2.4% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -46.2% vs 4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -43.3% vs -0.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -41.7% vs -7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -64.5% vs -7.6% wk 12 · n 93 · Phase 4 · secondary NCT02984982
  • -63.9% vs -13.4% wk 36 · n 93 · Phase 4 · secondary NCT02984982
-49.3% vs 4.2%−53.5 vs placebowk 72.9 · n 810NCT03400800
76 other results
  • -56.3% vs 1.3% wk 72.9 · n 781 · Phase 3 · primary NCT03399370
  • -45.8% vs 3.4% n 810 · Phase 3 · primary NCT03400800
  • -51.3% vs 2.5% n 781 · Phase 3 · primary NCT03399370
  • -45.9% vs 1.6% wk 21.43 · n 103 · Phase 3 · primary NCT05888103
  • -27.1% vs 1.4% wk 47.14 · n 93 · Phase 3 · primary NCT04652726
  • -41.1% vs 8.4% wk 73 · n 242 · Phase 3 · primary NCT03397121
  • -38.1% vs 6.2% n 242 · Phase 3 · primary NCT03397121
  • 0.7% vs 2.4% wk 21.43 · n 37 · Phase 3 · primary NCT03851705
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · primary NCT04659863
  • -45.6% vs 1.4% wk 47 · n 171 · Phase 3 · primary NCT04873934
  • -60% vs -7% wk 47 · n 205 · Phase 3 · primary NCT04929249
  • -23.9% vs -0.1% wk 12.86 · n 93 · Phase 3 · secondary NCT04652726
  • -8.7% vs 3.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -32.5% vs 6.4% wk 21.43 · n 93 · Phase 3 · secondary NCT04652726
  • 1.8% vs -2.9% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -7.2% vs -1.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -19% vs 2.1% wk 38.57 · n 93 · Phase 3 · secondary NCT04652726
  • -26.0% vs 3.3% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -27.8% vs 1.5% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -26.1% vs 1.5% wk 51.43 · n 93 · Phase 3 · secondary NCT04652726
  • -26.1% vs 6.8% wk 12.86 · n 9 · Phase 3 · secondary NCT04659863
  • -24.1% vs 17% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -17.3% vs 10.2% wk 38.57 · n 9 · Phase 3 · secondary NCT04659863
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -19.3% vs 5.4% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -44.3% vs 2.4% n 194 · Phase 3 · secondary NCT04873934
  • -57.2% vs -2.8% n 222 · Phase 3 · secondary NCT04929249
  • -38.4% vs 2.1% 300 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -52.6% vs 2.1% 300 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -56.3% vs 9% 300 mg · wk 25.714 · n 96 · Phase 2 · primary NCT04666298
  • -41.9% vs 2.1% 500 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -27.9% vs 2.1% 200 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -44.9% vs 2.1% 200 mg double dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -51.9% vs 9% 200 mg · wk 25.714 · n 101 · Phase 2 · primary NCT04666298
  • -35.5% vs 2.1% 100 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -47.6% vs 9% 100 mg · wk 25.714 · n 55 · Phase 2 · primary NCT04666298
  • -59.5% vs -24.3% wk 51.4 · n 898 · Phase 4 · secondary NCT05192941
  • -47.6% vs 1.7% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -62.8% vs 1.3% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -62.4% vs 0.2% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -50.9% vs -4.3% 300 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -51.0% vs -4.3% 300 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -61.5% vs 2.7% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -65.7% vs 1.2% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -67.2% vs 2.3% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -43.3% vs -0.9% 300 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -54.7% vs -0.9% 300 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -66.2% vs 4.3% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -35.4% vs 1.4% 300 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -50.5% vs 1.4% 300 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
  • -49.6% vs -4.3% 500 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -46.4% vs -0.9% 500 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -39.2% vs 1.4% 500 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -42.1% vs 1.7% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -55.5% vs 1.3% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -55.6% vs 0.2% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.3% vs -4.3% 200 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -44.3% vs -4.3% 200 mg double dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -53.9% vs 2.7% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -60.3% vs 1.2% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -62.0% vs 2.3% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -36.9% vs -0.9% 200 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -49.5% vs -0.9% 200 mg double dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -60.5% vs 4.3% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -29.0% vs 1.4% 200 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -42.6% vs 1.4% 200 mg double dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -37.1% vs 1.7% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
  • -52.2% vs 1.3% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -50.1% vs 0.2% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -35.7% vs -4.3% 100 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -46.4% vs 2.7% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -53% vs 1.2% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -54.9% vs 2.3% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -41.4% vs -0.9% 100 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -55.5% vs 4.3% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -31.7% vs 1.4% 100 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
Non-HDL-C, % change-51.6% vs 0.7%−52.3 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
87 other results
  • -53.1% vs 0.6% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -53.7% vs 0.9% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -43.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -49.7% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -48.9% vs 0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -52.6% vs 0.2% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -49.9% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -46.5% vs 0.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -42.8% vs 9.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -43.3% vs 9.4% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -38.4% vs 5.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -41.9% vs -6.2% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -41.7% vs -6.1% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -39.1% vs -1.6% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.5% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -41.4% vs -6.9% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -37.4% vs 2.6% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -42.6% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -43.2% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -37.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -44.2% vs 4.8% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -46.7% vs 5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -36.2% vs -4.9% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -4.9% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -35.9% vs -3.5% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -3.5% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -34.9% vs 3% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -45.3% vs 4.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -46.9% vs 5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -45.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -47.2% vs 4.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -50.1% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -54.9% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -56% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.4% vs 3% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -47.3% vs 3.9% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -56.3% vs -1.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -35.7% vs 4.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -47.1% vs 2.8% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -41.6% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -37.9% vs 4.1% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -43.6% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -47.2% vs 0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -44.4% vs 0.2% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -45.8% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -37.4% vs 0.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -42.1% vs -19.2% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -43.7% vs -20.2% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -42.6% vs -20.6% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -47% vs -19.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -49.1% vs -20.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -47.4% vs -20.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -40.6% vs -15.1% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -42.5% vs -16.7% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -40.2% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -46.9% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -41.5% vs -15.8% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -42.7% vs -11.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -31.4% vs -11.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -45.7% vs -14.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -35.6% vs -14.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -36.7% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -47.6% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -40.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -50.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -41.2% vs -18% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -29.8% vs -18% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -40.6% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -42.3% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -37.3% vs -4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · primary NCT02642159
  • -37% vs 2.5% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.6% vs 1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -41.1% vs 1.7% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -44% vs 2.2% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.4% vs 0.7% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -35.5% vs -9.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -54.5% vs -14.1% wk 36 · n 93 · Phase 4 · secondary NCT02984982
-41.2% vs 2.1%−43.3 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -47.4% vs -0.1% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -34.9% vs 7.4% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -24% vs 1.2% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -25.0% vs 1.8% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -25.7% vs 1.8% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -6.2% vs -1.1% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -29% vs 5.1% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -40.7% vs -0.1% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • 1.3% vs -1.7% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • 0.4% vs 2.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -7.2% vs 2.9% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -20.1% vs 7.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -23.3% vs 9.4% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -24% vs 19% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -54.0% vs 1.3% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -56.8% vs 2.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -58.7% vs 0.8% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -57.7% vs 2.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -53.2% vs 1.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -54.1% vs 0.6% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -54.2% vs 1.0% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -41.2% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -50.1% vs 1.3% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -52.9% vs 2.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -53.5% vs 0.8% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -52.0% vs 2.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -47.2% vs 1.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.6% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -48.0% vs 1.0% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -35.7% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -44.8% vs 1.3% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -47.9% vs 2.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.8% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -46.1% vs 2.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.8% vs 1.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 0.6% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -44.7% vs 1.0% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -31.4% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
ApoB, % change-52.8% vs 1.2%−54 vs placebo150 mg Q2W · wk 24 · n 1468NCT01507831
86 other results
  • -54.3% vs 1.2% 150 mg Q2W · wk 24 · n 1444 · Phase 3 · secondary NCT01507831
  • -55.5% vs 0.5% 150 mg Q2W · wk 12 · n 1468 · Phase 3 · secondary NCT01507831
  • -40.2% vs -0.7% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01926782
  • -45.1% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 292 · Phase 3 · secondary NCT01926782
  • -44.8% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -47.2% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 286 · Phase 3 · secondary NCT01926782
  • -46.4% vs -2.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 138 · Phase 3 · secondary NCT01926782
  • -41.2% vs 3.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 292 · Phase 3 · secondary NCT01926782
  • -41.1% vs 4.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 309 · Phase 3 · secondary NCT01623115
  • -41.4% vs 4.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01623115
  • -34.5% vs 3.1% 75 mg/Up to 150 mg Q2W · wk 12 · n 309 · Phase 3 · secondary NCT01623115
  • -39% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -38.9% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -36.7% vs -0.9% 75/150 mg Q2W · wk 24 · n 185 · Phase 3 · secondary NCT01644175
  • -37.9% vs -0.4% 75/150 mg Q2W · wk 24 · n 181 · Phase 3 · secondary NCT01644175
  • -39.2% vs -9% 150 mg Q2W · wk 12 · n 69 · Phase 3 · secondary NCT01617655
  • -34.8% vs 3.4% 75/150 mg Q2W · wk 12 · n 185 · Phase 3 · secondary NCT01644175
  • -42.8% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 163 · Phase 3 · secondary NCT01709500
  • -43.2% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 162 · Phase 3 · secondary NCT01709500
  • -33.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 279 · Phase 3 · secondary NCT02585778
  • -38.9% vs 7.5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -40.9% vs 7.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 54 · Phase 3 · secondary NCT02023879
  • -32.2% vs -6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -57.9% vs -6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.8% vs -4.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -58% vs -4.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.3% vs 7% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -39.7% vs 7.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -41.2% vs 7.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -39.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 96 · Phase 3 · secondary NCT02289963
  • -45.4% vs 3.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 95 · Phase 3 · secondary NCT02289963
  • -55% vs -1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT02107898
  • -55.9% vs -2.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 140 · Phase 3 · secondary NCT02107898
  • -38.4% vs 7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 112 · Phase 3 · secondary NCT02023879
  • -40.9% vs 5.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 96 · Phase 3 · secondary NCT02289963
  • -54.6% vs -3.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT02107898
  • -33.8% vs 1.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -42.8% vs 1.2% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -36.7% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -35.4% vs -0.9% 75 mg/up to 150 mg · wk 12 · n 163 · Phase 3 · secondary NCT01709500
  • -39% vs -0.7% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 34 · Phase 3 · secondary NCT01926782
  • -42% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -38.3% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 74 · Phase 3 · secondary NCT01926782
  • -40.8% vs -2.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 34 · Phase 3 · secondary NCT01926782
  • -33% vs 3.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -40.7% vs -18.3% 75 /up to 150 mg Q2W · wk 24 · n 452 · Phase 3 · secondary NCT01644188
  • -42.1% vs -19.1% 75 /up to 150 mg Q2W · wk 24 · n 442 · Phase 3 · secondary NCT01644188
  • -39.7% vs -17.2% 75 /up to 150 mg Q2W · wk 12 · n 452 · Phase 3 · secondary NCT01644188
  • -43.5% vs -16.2% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 398 · Phase 3 · secondary NCT02715726
  • -45.2% vs -17.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 392 · Phase 3 · secondary NCT02715726
  • -43% vs -16.5% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 398 · Phase 3 · secondary NCT02715726
  • -36.7% vs -11% 75/Up to 150 mg Q2W · wk 24 · n 48 · Phase 3 · secondary NCT01644474
  • -37.3% vs -11.7% 75/Up to 150 mg Q2W · wk 12 · n 48 · Phase 3 · secondary NCT01644474
  • -36.3% vs -11.2% 75 mg/ up to 150 mg · wk 24 · n 122 · Phase 3 · secondary NCT01709513
  • -42.6% vs -14.4% 75 mg/ up to 150 mg · wk 24 · n 109 · Phase 3 · secondary NCT01709513
  • -36.1% vs -11.6% 75 mg/ up to 150 mg · wk 12 · n 122 · Phase 3 · secondary NCT01709513
  • -36.5% vs -9.8% 75 mg/up to 150 mg + 10 mg · wk 24 · n 44 · Phase 3 · secondary NCT01730053
  • -28.3% vs -9.8% 75 mg/up to 150 mg + 20 mg · wk 24 · n 49 · Phase 3 · secondary NCT01730053
  • -39.5% vs -12.7% 75 mg/up to 150 mg + 10 mg · wk 24 · n 43 · Phase 3 · secondary NCT01730053
  • -30.4% vs -12.7% 75 mg/up to 150 mg + 20 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -33.7% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730040
  • -41.9% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 42 · Phase 3 · secondary NCT01730040
  • -37.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 50 · Phase 3 · secondary NCT01730040
  • -42.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 41 · Phase 3 · secondary NCT01730040
  • -36.1% vs -13.7% 75 mg/up to 150 mg + 10 mg · wk 12 · n 44 · Phase 3 · secondary NCT01730053
  • -29% vs -13.7% 75 mg/up to 150 mg + 20 mg · wk 12 · n 49 · Phase 3 · secondary NCT01730053
  • -38.4% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730040
  • -36.2% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 42 · Phase 3 · secondary NCT01730040
  • -36.4% vs 1.4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -39.1% vs 0.2% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -39% vs 1.1% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.9% vs 2.1% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.7% vs 0.8% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -33.8% vs -1.6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.1% vs -16.6% wk 36 · n 92 · Phase 4 · secondary NCT02984982
-38.1% vs 0.8%−38.9 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -44.8% vs -1.7% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -33.1% vs 2.9% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -19.3% vs 1.7% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -21.5% vs 4.2% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -21.9% vs 3.9% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -5.8% vs 4.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -25.1% vs 2.2% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -36.6% vs 0.2% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -0.7% vs 2.8% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -0.8% vs 3.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -6.4% vs 6.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -14.8% vs 10.6% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -18.5% vs 4.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -20.3% vs 10% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -46.8% vs 3.8% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -50.4% vs 3.9% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 2.0% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 3.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -46.8% vs 2.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -48.5% vs 1.4% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -48.8% vs 2.2% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -37.1% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -44.5% vs 3.8% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -46.7% vs 3.9% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 2.0% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -47.0% vs 3.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -42.0% vs 2.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -44.5% vs 1.4% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.0% vs 2.2% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -32.5% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -38.6% vs 3.8% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -42.8% vs 3.9% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 2.0% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -40.9% vs 3.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -35.8% vs 2.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.9% vs 1.4% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -39.7% vs 2.2% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -28.2% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
Lp(a), % change-29.3% vs -3.7%−25.6 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
64 other results
  • -28.2% vs -3.1% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -21.3% vs 6.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -19.3% vs 9.8% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -28.9% vs -5.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -19.6% vs 7% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -23.5% vs -8.7% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -20.5% vs -5.9% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -23.2% vs -1.5% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -19.7% vs 0% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -25.2% vs -7.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -15.5% vs 4.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -31.7% vs 1.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -49.6% vs 1.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -5.7% vs 2.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -30.3% vs -10% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -21.8% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -19% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -21.2% vs -3.9% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -24.7% vs -5.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -6.1% vs -1.2% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -18.1% vs -4% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -14% vs 6.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -16.9% vs 9.8% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -23% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -35.9% vs -2.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -39.5% vs 2.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -26.9% vs -5.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -12.4% vs 7% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -16.5% vs 2.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -33.6% vs -1.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -41.9% vs -0.5% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16.0% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -27.8% vs -6.1% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -22.1% vs 1.1% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -30.3% vs 4.0% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -30.1% vs 6.3% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -16.7% vs -12.3% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -17.2% vs -14.2% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -25.9% vs -7.3% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -21.7% vs -4.5% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -27.9% vs -5.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -22.7% vs -5.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -23.6% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -30.8% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -20.7% vs 3.5% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -16% vs 3.5% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -24% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -27.9% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -17.7% vs 4.8% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -25.1% vs -1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.3% vs -1.4% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.7% vs -0.5% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -22.4% vs -3.3% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -23.7% vs 3.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.8% vs -17.2% wk 36 · n 92 · Phase 4 · secondary NCT02984982
-9.3% vs 3.6%−12.9 vs placebowk 51.43 · n 92NCT04652726
34 other results
  • -5.0% vs 1.1% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -7.2% vs 1.1% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -4.8% vs 4.9% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -13.4% vs 5.4% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -23.8% vs 6.4% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -3.8% vs 15.2% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -4.6% vs 4.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -1.7% vs -12.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -0.3% vs -16.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -0.7% vs -4.4% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -35.4% vs 5.5% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -38.1% vs 4.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -37.2% vs 0.2% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -37.9% vs -2.4% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -34.3% vs 4.3% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -36.2% vs -4.3% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -31.3% vs 0.9% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -22.8% vs 3.3% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -25.5% vs 5.5% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -21.6% vs 4.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -30.3% vs 0.2% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -26.0% vs -2.4% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -24.9% vs 4.3% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -26.1% vs -4.3% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -22.8% vs 0.9% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -16.6% vs 3.3% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -30.1% vs 5.5% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -32.2% vs 4.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -31.5% vs 0.2% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -32.0% vs -2.4% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -27.1% vs 4.3% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -30.9% vs -4.3% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -28.1% vs 0.9% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -21.8% vs 3.3% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
3-point MACE (% with event)—Not posted · NCT04790513—Not posted · NCT05004675

LDL-C, % change

Alirocumab
-52.7% vs -0.3%−52.4 vs placebo300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144NCT01926782
165 other results
  • -58.8% vs -0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · primary NCT01926782
  • -45.7% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · primary NCT01617655
  • -48.2% vs -2.3% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · primary NCT01644175
  • -48.8% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · primary NCT01623115
  • -48.7% vs 2.8% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · primary NCT01709500
  • -48.2% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · primary NCT02585778
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · primary NCT03156621
  • -43.8% vs -4.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · primary NCT02584504
  • -70.1% vs -4.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · primary NCT02584504
  • -51.7% vs 4.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · primary NCT02023879
  • -50.2% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · primary NCT01926782
  • -51.6% vs -0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · primary NCT01926782
  • -51.8% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · primary NCT02585778
  • -57.1% vs 6.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · primary NCT02289963
  • -62.5% vs 1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · primary NCT02107898
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · primary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · primary NCT03510884
  • -50.6% vs -20.7% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · primary NCT01644188
  • -56% vs -20.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · primary NCT02715726
  • -47.2% vs -15.6% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · primary NCT01644474
  • -45% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · primary NCT01709513
  • -50.6% vs -15.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · primary NCT01730053
  • -36.3% vs -15.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · primary NCT01730053
  • -44.1% vs -5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · primary NCT01730040
  • -54% vs -5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · primary NCT01730040
  • -55.8% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9462 · Phase 3 · secondary NCT01663402
  • -58.3% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9451 · Phase 3 · secondary NCT01663402
  • -45.7% vs 8% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9462 · Phase 3 · secondary NCT01663402
  • -52.8% vs 8.2% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9451 · Phase 3 · secondary NCT01663402
  • -23.5% vs 16.4% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9462 · Phase 3 · secondary NCT01663402
  • -40.1% vs 14.6% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9451 · Phase 3 · secondary NCT01663402
  • -63.3% vs 1.5% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -64.2% vs 1.4% 150 mg Q2W · wk 12 · n 1523 · Phase 3 · secondary NCT01507831
  • -61% vs 0.8% 150 mg Q2W · wk 24 · n 1530 · Phase 3 · secondary NCT01507831
  • -62.8% vs 0.7% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -57.8% vs 3.5% 150 mg Q2W · wk 24 · n 1278 · Phase 3 · secondary NCT01507831
  • -56.8% vs 4.4% 150 mg Q2W · wk 52 · n 1530 · Phase 3 · secondary NCT01507831
  • -59.9% vs 4.6% 150 mg Q2W · wk 52 · n 1523 · Phase 3 · secondary NCT01507831
  • -52.4% vs 3.6% 150 mg Q2W · wk 78 · n 1530 · Phase 3 · secondary NCT01507831
  • -58% vs 3.9% 150 mg Q2W · wk 78 · n 1523 · Phase 3 · secondary NCT01507831
  • -58.4% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -55.3% vs 1.1% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -60% vs -0.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT01926782
  • -58% vs 1.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 302 · Phase 3 · secondary NCT01926782
  • -59.4% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -62.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -43.5% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -43.8% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -44.2% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -49.4% vs 2.7% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -47.1% vs 9% 75 mg/Up to 150 mg Q2W · wk 52 · n 322 · Phase 3 · secondary NCT01623115
  • -40.3% vs 11.5% 75 mg/Up to 150 mg Q2W · wk 78 · n 322 · Phase 3 · secondary NCT01623115
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.3% vs 1.1% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -47.6% vs 1.7% 75/150 mg Q2W · wk 12 · n 204 · Phase 3 · secondary NCT01644175
  • -45.5% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -50.7% vs -0.8% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -43.9% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 321 · Phase 3 · secondary NCT01623115
  • -55.1% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -50.3% vs 8.4% 75 mg/up to 150 mg · wk 52 · n 166 · Phase 3 · secondary NCT01709500
  • -43.7% vs 14% 75 mg/Up to 150 mg Q2W · wk 78 · n 321 · Phase 3 · secondary NCT01623115
  • -42.1% vs -3% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42% vs -2.9% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42.5% vs 0.5% 75/150 mg Q2W · wk 52 · n 205 · Phase 3 · secondary NCT01644175
  • -49.3% vs 8.8% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -48.1% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 52 · n 321 · Phase 3 · secondary NCT01623115
  • -53.7% vs 1.6% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -43.4% vs -2.8% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -70.1% vs -2.8% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54.2% vs -3.7% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -3.7% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54% vs -2.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -2.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -41.7% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -44.8% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 57 · Phase 3 · secondary NCT02023879
  • -42.3% vs 4% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -54.6% vs 5.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -40.9% vs -0.2% 150 mg Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -52.3% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · n 58 · Phase 3 · secondary NCT02023879
  • -55% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · n 57 · Phase 3 · secondary NCT02023879
  • -51.8% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -45.3% vs 1.1% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -53.9% vs -0.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -47.3% vs 1.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -50.8% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -51.5% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -48.8% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 284 · Phase 3 · secondary NCT02585778
  • -44.8% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 275 · Phase 3 · secondary NCT02585778
  • -55.3% vs 5.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -50.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 284 · Phase 3 · secondary NCT02585778
  • -43.3% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 277 · Phase 3 · secondary NCT02585778
  • -49.4% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 49 · Phase 3 · secondary NCT02585778
  • -64.2% vs -2.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -64.8% vs -2.8% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -63.7% vs 1.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -46.7% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 45 · Phase 3 · secondary NCT02585778
  • -57.9% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -58.4% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -53.8% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -49.4% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -60.2% vs 6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -62.5% vs -3.6% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -64.6% vs -3.4% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -53.6% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.1% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.6% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -37.9% vs 1.2% 150 Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -51.2% vs -21.8% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -52.4% vs -22.7% 75 /up to 150 mg Q2W · wk 12 · n 464 · Phase 3 · secondary NCT01644188
  • -52.4% vs -21.8% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -49.5% vs -18.3% 75 /up to 150 mg Q2W · wk 52 · n 467 · Phase 3 · secondary NCT01644188
  • -51.8% vs -19.7% 75 /up to 150 mg Q2W · wk 52 · n 464 · Phase 3 · secondary NCT01644188
  • -44.2% vs -15.2% 75 /up to 150 mg Q2W · wk 104 · n 467 · Phase 3 · secondary NCT01644188
  • -48.9% vs -17% 75 /up to 150 mg Q2W · wk 104 · n 464 · Phase 3 · secondary NCT01644188
  • -57.1% vs -22.2% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -58.1% vs -22.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 401 · Phase 3 · secondary NCT02715726
  • -58.7% vs -21.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -48.1% vs -19.6% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -47% vs -15.6% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -51.2% vs -18% 75 mg/ up to 150 mg · wk 12 · n 123 · Phase 3 · secondary NCT01709513
  • -52.2% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -47.3% vs -15.2% 75 mg/ up to 150 mg · wk 24 · n 112 · Phase 3 · secondary NCT01709513
  • -49.6% vs -22.1% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -32.3% vs -22.1% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -52.6% vs -22.9% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -35.1% vs -22.9% 75 mg/up to 150 mg + 20 mg · wk 12 · n 51 · Phase 3 · secondary NCT01730053
  • -48.4% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -50.5% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -53.7% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 52 · Phase 3 · secondary NCT01730040
  • -50.9% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -53.5% vs -17% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -41.5% vs -17% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -48.6% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -57.8% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -66.2% vs -51.2% wk 4 · n 31 · Phase 3 · secondary NCT03415178
  • -73% vs 2% wk 2 · n 10 · Phase 4 · primary NCT02938949
  • -49.6% vs 0.6% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -54.2% vs 3% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -51.4% vs 2.8% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -50.4% vs 2.4% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -46.2% vs 4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -43.3% vs -0.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -41.7% vs -7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -64.5% vs -7.6% wk 12 · n 93 · Phase 4 · secondary NCT02984982
  • -63.9% vs -13.4% wk 36 · n 93 · Phase 4 · secondary NCT02984982
Inclisiran
-49.3% vs 4.2%−53.5 vs placebowk 72.9 · n 810NCT03400800
76 other results
  • -56.3% vs 1.3% wk 72.9 · n 781 · Phase 3 · primary NCT03399370
  • -45.8% vs 3.4% n 810 · Phase 3 · primary NCT03400800
  • -51.3% vs 2.5% n 781 · Phase 3 · primary NCT03399370
  • -45.9% vs 1.6% wk 21.43 · n 103 · Phase 3 · primary NCT05888103
  • -27.1% vs 1.4% wk 47.14 · n 93 · Phase 3 · primary NCT04652726
  • -41.1% vs 8.4% wk 73 · n 242 · Phase 3 · primary NCT03397121
  • -38.1% vs 6.2% n 242 · Phase 3 · primary NCT03397121
  • 0.7% vs 2.4% wk 21.43 · n 37 · Phase 3 · primary NCT03851705
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · primary NCT04659863
  • -45.6% vs 1.4% wk 47 · n 171 · Phase 3 · primary NCT04873934
  • -60% vs -7% wk 47 · n 205 · Phase 3 · primary NCT04929249
  • -23.9% vs -0.1% wk 12.86 · n 93 · Phase 3 · secondary NCT04652726
  • -8.7% vs 3.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -32.5% vs 6.4% wk 21.43 · n 93 · Phase 3 · secondary NCT04652726
  • 1.8% vs -2.9% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -7.2% vs -1.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -19% vs 2.1% wk 38.57 · n 93 · Phase 3 · secondary NCT04652726
  • -26.0% vs 3.3% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -27.8% vs 1.5% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -26.1% vs 1.5% wk 51.43 · n 93 · Phase 3 · secondary NCT04652726
  • -26.1% vs 6.8% wk 12.86 · n 9 · Phase 3 · secondary NCT04659863
  • -24.1% vs 17% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -17.3% vs 10.2% wk 38.57 · n 9 · Phase 3 · secondary NCT04659863
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -19.3% vs 5.4% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -44.3% vs 2.4% n 194 · Phase 3 · secondary NCT04873934
  • -57.2% vs -2.8% n 222 · Phase 3 · secondary NCT04929249
  • -38.4% vs 2.1% 300 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -52.6% vs 2.1% 300 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -56.3% vs 9% 300 mg · wk 25.714 · n 96 · Phase 2 · primary NCT04666298
  • -41.9% vs 2.1% 500 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -27.9% vs 2.1% 200 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -44.9% vs 2.1% 200 mg double dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -51.9% vs 9% 200 mg · wk 25.714 · n 101 · Phase 2 · primary NCT04666298
  • -35.5% vs 2.1% 100 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -47.6% vs 9% 100 mg · wk 25.714 · n 55 · Phase 2 · primary NCT04666298
  • -59.5% vs -24.3% wk 51.4 · n 898 · Phase 4 · secondary NCT05192941
  • -47.6% vs 1.7% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -62.8% vs 1.3% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -62.4% vs 0.2% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -50.9% vs -4.3% 300 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -51.0% vs -4.3% 300 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -61.5% vs 2.7% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -65.7% vs 1.2% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -67.2% vs 2.3% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -43.3% vs -0.9% 300 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -54.7% vs -0.9% 300 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -66.2% vs 4.3% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -35.4% vs 1.4% 300 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -50.5% vs 1.4% 300 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
  • -49.6% vs -4.3% 500 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -46.4% vs -0.9% 500 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -39.2% vs 1.4% 500 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -42.1% vs 1.7% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -55.5% vs 1.3% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -55.6% vs 0.2% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.3% vs -4.3% 200 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -44.3% vs -4.3% 200 mg double dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -53.9% vs 2.7% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -60.3% vs 1.2% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -62.0% vs 2.3% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -36.9% vs -0.9% 200 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -49.5% vs -0.9% 200 mg double dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -60.5% vs 4.3% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -29.0% vs 1.4% 200 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -42.6% vs 1.4% 200 mg double dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -37.1% vs 1.7% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
  • -52.2% vs 1.3% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -50.1% vs 0.2% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -35.7% vs -4.3% 100 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -46.4% vs 2.7% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -53% vs 1.2% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -54.9% vs 2.3% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -41.4% vs -0.9% 100 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -55.5% vs 4.3% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -31.7% vs 1.4% 100 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127

Non-HDL-C, % change

Alirocumab
-51.6% vs 0.7%−52.3 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
87 other results
  • -53.1% vs 0.6% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -53.7% vs 0.9% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -43.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -49.7% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -48.9% vs 0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -52.6% vs 0.2% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -49.9% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -46.5% vs 0.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -42.8% vs 9.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -43.3% vs 9.4% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -38.4% vs 5.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -41.9% vs -6.2% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -41.7% vs -6.1% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -39.1% vs -1.6% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.5% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -41.4% vs -6.9% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -37.4% vs 2.6% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -42.6% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -43.2% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -37.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -44.2% vs 4.8% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -46.7% vs 5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -36.2% vs -4.9% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -4.9% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -35.9% vs -3.5% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -3.5% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -34.9% vs 3% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -45.3% vs 4.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -46.9% vs 5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -45.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -47.2% vs 4.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -50.1% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -54.9% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -56% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.4% vs 3% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -47.3% vs 3.9% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -56.3% vs -1.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -35.7% vs 4.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -47.1% vs 2.8% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -41.6% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -37.9% vs 4.1% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -43.6% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -47.2% vs 0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -44.4% vs 0.2% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -45.8% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -37.4% vs 0.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -42.1% vs -19.2% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -43.7% vs -20.2% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -42.6% vs -20.6% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -47% vs -19.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -49.1% vs -20.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -47.4% vs -20.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -40.6% vs -15.1% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -42.5% vs -16.7% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -40.2% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -46.9% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -41.5% vs -15.8% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -42.7% vs -11.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -31.4% vs -11.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -45.7% vs -14.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -35.6% vs -14.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -36.7% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -47.6% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -40.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -50.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -41.2% vs -18% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -29.8% vs -18% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -40.6% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -42.3% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -37.3% vs -4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · primary NCT02642159
  • -37% vs 2.5% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.6% vs 1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -41.1% vs 1.7% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -44% vs 2.2% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.4% vs 0.7% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -35.5% vs -9.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -54.5% vs -14.1% wk 36 · n 93 · Phase 4 · secondary NCT02984982
Inclisiran
-41.2% vs 2.1%−43.3 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -47.4% vs -0.1% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -34.9% vs 7.4% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -24% vs 1.2% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -25.0% vs 1.8% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -25.7% vs 1.8% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -6.2% vs -1.1% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -29% vs 5.1% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -40.7% vs -0.1% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • 1.3% vs -1.7% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • 0.4% vs 2.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -7.2% vs 2.9% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -20.1% vs 7.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -23.3% vs 9.4% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -24% vs 19% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -54.0% vs 1.3% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -56.8% vs 2.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -58.7% vs 0.8% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -57.7% vs 2.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -53.2% vs 1.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -54.1% vs 0.6% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -54.2% vs 1.0% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -41.2% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -50.1% vs 1.3% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -52.9% vs 2.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -53.5% vs 0.8% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -52.0% vs 2.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -47.2% vs 1.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.6% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -48.0% vs 1.0% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -35.7% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -44.8% vs 1.3% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -47.9% vs 2.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.8% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -46.1% vs 2.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.8% vs 1.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 0.6% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -44.7% vs 1.0% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -31.4% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298

ApoB, % change

Alirocumab
-52.8% vs 1.2%−54 vs placebo150 mg Q2W · wk 24 · n 1468NCT01507831
86 other results
  • -54.3% vs 1.2% 150 mg Q2W · wk 24 · n 1444 · Phase 3 · secondary NCT01507831
  • -55.5% vs 0.5% 150 mg Q2W · wk 12 · n 1468 · Phase 3 · secondary NCT01507831
  • -40.2% vs -0.7% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01926782
  • -45.1% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 292 · Phase 3 · secondary NCT01926782
  • -44.8% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -47.2% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 286 · Phase 3 · secondary NCT01926782
  • -46.4% vs -2.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 138 · Phase 3 · secondary NCT01926782
  • -41.2% vs 3.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 292 · Phase 3 · secondary NCT01926782
  • -41.1% vs 4.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 309 · Phase 3 · secondary NCT01623115
  • -41.4% vs 4.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01623115
  • -34.5% vs 3.1% 75 mg/Up to 150 mg Q2W · wk 12 · n 309 · Phase 3 · secondary NCT01623115
  • -39% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -38.9% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -36.7% vs -0.9% 75/150 mg Q2W · wk 24 · n 185 · Phase 3 · secondary NCT01644175
  • -37.9% vs -0.4% 75/150 mg Q2W · wk 24 · n 181 · Phase 3 · secondary NCT01644175
  • -39.2% vs -9% 150 mg Q2W · wk 12 · n 69 · Phase 3 · secondary NCT01617655
  • -34.8% vs 3.4% 75/150 mg Q2W · wk 12 · n 185 · Phase 3 · secondary NCT01644175
  • -42.8% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 163 · Phase 3 · secondary NCT01709500
  • -43.2% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 162 · Phase 3 · secondary NCT01709500
  • -33.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 279 · Phase 3 · secondary NCT02585778
  • -38.9% vs 7.5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -40.9% vs 7.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 54 · Phase 3 · secondary NCT02023879
  • -32.2% vs -6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -57.9% vs -6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.8% vs -4.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -58% vs -4.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.3% vs 7% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -39.7% vs 7.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -41.2% vs 7.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -39.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 96 · Phase 3 · secondary NCT02289963
  • -45.4% vs 3.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 95 · Phase 3 · secondary NCT02289963
  • -55% vs -1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT02107898
  • -55.9% vs -2.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 140 · Phase 3 · secondary NCT02107898
  • -38.4% vs 7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 112 · Phase 3 · secondary NCT02023879
  • -40.9% vs 5.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 96 · Phase 3 · secondary NCT02289963
  • -54.6% vs -3.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT02107898
  • -33.8% vs 1.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -42.8% vs 1.2% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -36.7% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -35.4% vs -0.9% 75 mg/up to 150 mg · wk 12 · n 163 · Phase 3 · secondary NCT01709500
  • -39% vs -0.7% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 34 · Phase 3 · secondary NCT01926782
  • -42% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -38.3% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 74 · Phase 3 · secondary NCT01926782
  • -40.8% vs -2.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 34 · Phase 3 · secondary NCT01926782
  • -33% vs 3.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -40.7% vs -18.3% 75 /up to 150 mg Q2W · wk 24 · n 452 · Phase 3 · secondary NCT01644188
  • -42.1% vs -19.1% 75 /up to 150 mg Q2W · wk 24 · n 442 · Phase 3 · secondary NCT01644188
  • -39.7% vs -17.2% 75 /up to 150 mg Q2W · wk 12 · n 452 · Phase 3 · secondary NCT01644188
  • -43.5% vs -16.2% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 398 · Phase 3 · secondary NCT02715726
  • -45.2% vs -17.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 392 · Phase 3 · secondary NCT02715726
  • -43% vs -16.5% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 398 · Phase 3 · secondary NCT02715726
  • -36.7% vs -11% 75/Up to 150 mg Q2W · wk 24 · n 48 · Phase 3 · secondary NCT01644474
  • -37.3% vs -11.7% 75/Up to 150 mg Q2W · wk 12 · n 48 · Phase 3 · secondary NCT01644474
  • -36.3% vs -11.2% 75 mg/ up to 150 mg · wk 24 · n 122 · Phase 3 · secondary NCT01709513
  • -42.6% vs -14.4% 75 mg/ up to 150 mg · wk 24 · n 109 · Phase 3 · secondary NCT01709513
  • -36.1% vs -11.6% 75 mg/ up to 150 mg · wk 12 · n 122 · Phase 3 · secondary NCT01709513
  • -36.5% vs -9.8% 75 mg/up to 150 mg + 10 mg · wk 24 · n 44 · Phase 3 · secondary NCT01730053
  • -28.3% vs -9.8% 75 mg/up to 150 mg + 20 mg · wk 24 · n 49 · Phase 3 · secondary NCT01730053
  • -39.5% vs -12.7% 75 mg/up to 150 mg + 10 mg · wk 24 · n 43 · Phase 3 · secondary NCT01730053
  • -30.4% vs -12.7% 75 mg/up to 150 mg + 20 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -33.7% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730040
  • -41.9% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 42 · Phase 3 · secondary NCT01730040
  • -37.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 50 · Phase 3 · secondary NCT01730040
  • -42.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 41 · Phase 3 · secondary NCT01730040
  • -36.1% vs -13.7% 75 mg/up to 150 mg + 10 mg · wk 12 · n 44 · Phase 3 · secondary NCT01730053
  • -29% vs -13.7% 75 mg/up to 150 mg + 20 mg · wk 12 · n 49 · Phase 3 · secondary NCT01730053
  • -38.4% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730040
  • -36.2% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 42 · Phase 3 · secondary NCT01730040
  • -36.4% vs 1.4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -39.1% vs 0.2% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -39% vs 1.1% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.9% vs 2.1% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.7% vs 0.8% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -33.8% vs -1.6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.1% vs -16.6% wk 36 · n 92 · Phase 4 · secondary NCT02984982
Inclisiran
-38.1% vs 0.8%−38.9 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -44.8% vs -1.7% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -33.1% vs 2.9% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -19.3% vs 1.7% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -21.5% vs 4.2% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -21.9% vs 3.9% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -5.8% vs 4.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -25.1% vs 2.2% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -36.6% vs 0.2% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -0.7% vs 2.8% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -0.8% vs 3.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -6.4% vs 6.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -14.8% vs 10.6% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -18.5% vs 4.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -20.3% vs 10% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -46.8% vs 3.8% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -50.4% vs 3.9% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 2.0% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 3.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -46.8% vs 2.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -48.5% vs 1.4% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -48.8% vs 2.2% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -37.1% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -44.5% vs 3.8% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -46.7% vs 3.9% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 2.0% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -47.0% vs 3.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -42.0% vs 2.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -44.5% vs 1.4% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.0% vs 2.2% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -32.5% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -38.6% vs 3.8% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -42.8% vs 3.9% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 2.0% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -40.9% vs 3.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -35.8% vs 2.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.9% vs 1.4% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -39.7% vs 2.2% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -28.2% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298

Lp(a), % change

Alirocumab
-29.3% vs -3.7%−25.6 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
64 other results
  • -28.2% vs -3.1% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -21.3% vs 6.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -19.3% vs 9.8% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -28.9% vs -5.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -19.6% vs 7% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -23.5% vs -8.7% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -20.5% vs -5.9% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -23.2% vs -1.5% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -19.7% vs 0% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -25.2% vs -7.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -15.5% vs 4.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -31.7% vs 1.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -49.6% vs 1.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -5.7% vs 2.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -30.3% vs -10% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -21.8% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -19% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -21.2% vs -3.9% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -24.7% vs -5.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -6.1% vs -1.2% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -18.1% vs -4% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -14% vs 6.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -16.9% vs 9.8% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -23% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -35.9% vs -2.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -39.5% vs 2.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -26.9% vs -5.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -12.4% vs 7% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -16.5% vs 2.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -33.6% vs -1.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -41.9% vs -0.5% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16.0% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -27.8% vs -6.1% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -22.1% vs 1.1% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -30.3% vs 4.0% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -30.1% vs 6.3% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -16.7% vs -12.3% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -17.2% vs -14.2% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -25.9% vs -7.3% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -21.7% vs -4.5% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -27.9% vs -5.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -22.7% vs -5.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -23.6% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -30.8% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -20.7% vs 3.5% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -16% vs 3.5% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -24% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -27.9% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -17.7% vs 4.8% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -25.1% vs -1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.3% vs -1.4% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.7% vs -0.5% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -22.4% vs -3.3% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -23.7% vs 3.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.8% vs -17.2% wk 36 · n 92 · Phase 4 · secondary NCT02984982
Inclisiran
-9.3% vs 3.6%−12.9 vs placebowk 51.43 · n 92NCT04652726
34 other results
  • -5.0% vs 1.1% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -7.2% vs 1.1% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -4.8% vs 4.9% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -13.4% vs 5.4% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -23.8% vs 6.4% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -3.8% vs 15.2% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -4.6% vs 4.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -1.7% vs -12.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -0.3% vs -16.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -0.7% vs -4.4% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -35.4% vs 5.5% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -38.1% vs 4.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -37.2% vs 0.2% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -37.9% vs -2.4% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -34.3% vs 4.3% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -36.2% vs -4.3% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -31.3% vs 0.9% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -22.8% vs 3.3% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -25.5% vs 5.5% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -21.6% vs 4.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -30.3% vs 0.2% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -26.0% vs -2.4% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -24.9% vs 4.3% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -26.1% vs -4.3% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -22.8% vs 0.9% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -16.6% vs 3.3% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -30.1% vs 5.5% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -32.2% vs 4.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -31.5% vs 0.2% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -32.0% vs -2.4% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -27.1% vs 4.3% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -30.9% vs -4.3% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -28.1% vs 0.9% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -21.8% vs 3.3% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298

3-point MACE (% with event)

Alirocumab
—Not posted · NCT04790513
Inclisiran
—Not posted · NCT05004675
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
28 other shared endpoints and safety

Coverage. Alirocumab: 32 of 32 rows · Inclisiran: 32 of 32 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlirocumab
Rows use multiple source trials
Inclisiran
Rows use multiple source trials
Apo A1
percent change · % of baseline
7.5% (n=1058) vs 4.2% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2Wa,b,c,d
NCT02957682 · Phase 4 · registry result, not featured evidence
3% (n=92) vs -1.5% (n=48) placebo @ 51.43wka,b,c,d
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Apo A1
percent change · % of baseline
No placebo or comparator arm
3.9% (n=651) @ 168wk75 or 150 mg Q2We,c,f
NCT01954394 · Phase 3 · registry result, not featured evidence
5.5% (n=34) @ 102.86wke,c,f
NCT03851705 · Phase 3 · registry result, not featured evidence
Apo B
percent change · % of baseline
No placebo or comparator arm
-43.1% (n=651) @ 168wk75 or 150 mg Q2Wg,e,c,h
NCT01954394 · Phase 3 · registry result, not featured evidence
-33.66% (n=277) @ 205.71wkg,e,c,h
NCT03060577 · Phase 2 · registry result, not featured evidence
Apo B Change mg/dL
absolute change · mg/dL
-51 vs -16.8 Standard of Care mg/dL @ 36wka,b,c,i
NCT02984982 · Phase 4 · registry result, not featured evidence
-26.1 vs -0.6 placebo mg/dL @ 51.43wka,b,c,i
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Apo B Change mg/dL
absolute change · mg/dL
No placebo or comparator arm
-63.5 mg/dL @ 8wk300 mg Q4Wj,e,c,k
NCT02890992 · Phase 2 · registry result, not featured evidence
show 7 more doses
-5.4 mg/dL @ 8wk150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
-34.2 mg/dL @ 8wk150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
-53.4 mg/dL @ 8wk75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-15.3 mg/dL @ 8wk75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
-18.5 mg/dL @ 8wk50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-35.3 mg/dL @ 8wk40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-51.7 mg/dL @ 8wk30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-36.26 mg/dL @ 205.71wke,c,k
NCT03060577 · Phase 2 · registry result, not featured evidence
Apo-A1 Change mg/dL
absolute change · mg/dL
12 vs 3.8 Standard of Care mg/dL @ 36wka,b,c,i
NCT02984982 · Phase 4 · registry result, not featured evidence
2.7 vs -2.6 placebo mg/dL @ 51.43wka,b,c,i
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Apo-A1 Change mg/dL
absolute change · mg/dL
No placebo or comparator arm
11 mg/dL @ 8wk300 mg Q4Wj,l,e,c,m
NCT02890992 · Phase 2 · registry result, not featured evidence
show 7 more doses
8 mg/dL @ 8wk150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
7.5 mg/dL @ 8wk150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
-0.4 mg/dL @ 8wk75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
10.5 mg/dL @ 8wk75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
17.7 mg/dL @ 8wk50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
11.3 mg/dL @ 8wk40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
4 mg/dL @ 8wk30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
6.9 mg/dL @ 102.86wkl,e,c,m
NCT03851705 · Phase 3 · registry result, not featured evidence
HDL-C
percent change · % of baseline
10.8% (n=1058) vs 5.5% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2Wa,b,c,d
NCT02957682 · Phase 4 · registry result, not featured evidence
4.4% (n=92) vs 0.9% (n=48) placebo @ 51.43wka,b,c,d
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
HDL-C
percent change · % of baseline
No placebo or comparator arm
-0.3% (n=651) @ 168wk75 or 150 mg Q2We,c,f
NCT01954394 · Phase 3 · registry result, not featured evidence
4.1% (n=34) @ 102.86wke,c,f
NCT03851705 · Phase 3 · registry result, not featured evidence
HDL-C Change mg/dL
absolute change · mg/dL
8.1 vs 4.7 Standard of Care mg/dL @ 36wka,b,c,i
NCT02984982 · Phase 4 · registry result, not featured evidence
1.5 vs -0.1 placebo mg/dL @ 51.43wka,b,c,i
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
HDL-C Change mg/dL
absolute change · mg/dL
No placebo or comparator arm
1.2 mg/dL @ 8wk300 mg Q4Wj,l,e,c,m
NCT02890992 · Phase 2 · registry result, not featured evidence
show 7 more doses
5.9 mg/dL @ 8wk150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
2.2 mg/dL @ 8wk150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
4.9 mg/dL @ 8wk75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
2.4 mg/dL @ 8wk75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
7.7 mg/dL @ 8wk50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
5.5 mg/dL @ 8wk40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
5.9 mg/dL @ 8wk30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0.8 mg/dL @ 102.86wkl,e,c,m
NCT03851705 · Phase 3 · registry result, not featured evidence
LDL-C
absolute change · mg/dL
-63.2 vs -15.5 Standard of Care mg/dL @ 36wka,b,c
NCT02984982 · Phase 4 · registry result, not featured evidence
-50.91 vs 0.96 placebo mg/dL @ 72.9wkj,a,b,c
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more dose
-48.63 vs 0.31 placebo mg/dL
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C
percent change · % of baseline
No placebo or comparator arm
-52.2% (n=651) @ 168wk75 or 150 mg Q2Wg,e,c,h
NCT01954394 · Phase 3 · registry result, not featured evidence
-46.74% (n=277) @ 205.71wkg,e,c,h
NCT03060577 · Phase 2 · registry result, not featured evidence
LDL-C
absolute change · mg/dL
No placebo or comparator arm
-99.4 mg/dL @ 168wk75 or 150 mg Q2Wg,e,c,h
NCT01954394 · Phase 3 · registry result, not featured evidence
-60.04 mg/dL @ 205.71wkg,e,c,h
NCT03060577 · Phase 2 · registry result, not featured evidence
LDL-C
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
-58.46% (n=14) @ 208wkl,e,c,n
NCT01576484 · Phase 2 · registry result, not featured evidence
-45.45% (n=103) @ 47.14wkl,e,c,n
NCT05888103 · Phase 3 · registry result, not featured evidence
LDL-C 50% Reduction
responder rate · % of participants
21.6% (n=49) vs 0% (n=25) placebo @ 24wkQ2Wj,b,c,o
NCT03510884 · Phase 3
show 3 more doses
21.6% (n=49) vs 0% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
32.4% (n=52) vs 0% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
32.4% (n=52) vs 0% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
45.3% (n=201) vs 6.5% (n=199) Usual Care @ 47wkb,c,o
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
69.8% (n=225) vs 5.3% (n=225) Usual Care @ 47wk
NCT04929249 · Phase 3 · registry result, not featured evidence
LDL-C Less Than 100
responder rate · % of participants
88.1% (n=52) vs 32.2% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2Wb,c,o
NCT01644474 · Phase 3
80.5% (n=77) vs 32.1% (n=81) Usual Care @ 47wkb,c,o
NCT04929249 · Phase 3 · registry result, not featured evidence
LDL-C Less Than 70
responder rate · % of participants
64.5% (n=1058) vs 10.7% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2Wa,b,c,p
NCT02957682 · Phase 4 · registry result, not featured evidence
66.7% (n=201) vs 28.1% (n=199) Usual Care @ 47wka,b,c,p
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
81.8% (n=225) vs 22.2% (n=225) Usual Care @ 47wk
NCT04929249 · Phase 3 · registry result, not featured evidence
Lp(a
percent change · % of baseline
No placebo or comparator arm
-29.2% (n=651) @ 168wk75 or 150 mg Q2Wg,e,c,h
NCT01954394 · Phase 3 · registry result, not featured evidence
-5.24% (n=277) @ 205.71wkg,e,c,h
NCT03060577 · Phase 2 · registry result, not featured evidence
Non-HDL-C
percent change · % of baseline
No placebo or comparator arm
-47.7% (n=651) @ 168wk75 or 150 mg Q2We,c,f
NCT01954394 · Phase 3 · registry result, not featured evidence
-13% (n=13) @ 102.86wke,c,f
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
1 other source trial
-5% (n=34) @ 102.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL
absolute change · mg/dL
-69.2 vs -20.3 Standard of Care mg/dL @ 36wka,b,c,i
NCT02984982 · Phase 4 · registry result, not featured evidence
-49.7 vs -3 placebo mg/dL @ 51.43wka,b,c,i
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Non-HDL-C Change mg/dL
absolute change · mg/dL
No placebo or comparator arm
-106.4 mg/dL @ 8wk300 mg Q4Wj,l,e,c,m
NCT02890992 · Phase 2 · registry result, not featured evidence
show 7 more doses
-0.6 mg/dL @ 8wk150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
-63.1 mg/dL @ 8wk150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
-88.5 mg/dL @ 8wk75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-29.5 mg/dL @ 8wk75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
-28.7 mg/dL @ 8wk50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-62.7 mg/dL @ 8wk40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-86.1 mg/dL @ 8wk30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-9.3 mg/dL @ 102.86wkl,e,c,m
NCT03851705 · Phase 3 · registry result, not featured evidence
Total Cholesterol
percent change · % of baseline
-35.43% (n=93) vs -7.59% (n=89) Standard of Care @ 36wka,b,c,q
NCT02984982 · Phase 4 · registry result, not featured evidence
-28% (n=810) vs 1.79% (n=807) placebo @ 72.9wka,b,c,q
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
1 other source trial
-33.56% (n=781) vs -0.42% (n=781) placebo @ 72.9wk
NCT03399370 · Phase 3
Total Cholesterol
percent change · % of baseline
No placebo or comparator arm
-39.1% (n=651) @ 168wk75 or 150 mg Q2We,c,f
NCT01954394 · Phase 3 · registry result, not featured evidence
-2.9% (n=34) @ 102.86wke,c,f
NCT03851705 · Phase 3 · registry result, not featured evidence
Total Cholesterol Change mg/dL
absolute change · mg/dL
-61.7 vs -15.2 Standard of Care mg/dL @ 36wka,b,c,i
NCT02984982 · Phase 4 · registry result, not featured evidence
-48.2 vs -3.1 placebo mg/dL @ 51.43wka,b,c,i
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Total Cholesterol Change mg/dL
absolute change · mg/dL
No placebo or comparator arm
-105.1 mg/dL @ 8wk300 mg Q4Wj,l,e,c,m
NCT02890992 · Phase 2 · registry result, not featured evidence
show 7 more doses
5.3 mg/dL @ 8wk150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
-60.7 mg/dL @ 8wk150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
-84.4 mg/dL @ 8wk75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-27.2 mg/dL @ 8wk75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
-20.8 mg/dL @ 8wk50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-57.1 mg/dL @ 8wk40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-80.1 mg/dL @ 8wk30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
-8.5 mg/dL @ 102.86wkl,e,c,m
NCT03851705 · Phase 3 · registry result, not featured evidence
Triglycerides
percent change · % of baseline
-2.4% (n=41) vs 4.1% (n=21) placebo @ 18wk150 mg Q2Wb,c,r
NCT02326220 · Phase 3
1.7% (n=92) vs 3.8% (n=48) placebo @ 51.43wkb,c,r
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Triglycerides
percent change · % of baseline
No placebo or comparator arm
-8.28% (n=921) @ 12wkg,e,c,s
NCT02476006 · Phase 3 · registry result, not featured evidence
0.73% (n=277) @ 205.71wkg,e,c,s
NCT03060577 · Phase 2 · registry result, not featured evidence
Dropout rate
28.3%150 mg Q2Wt
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
40.3%150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—75 /up to 150 mg Q2W
NCT01644175 · Phase 3
25.4%75/150 mg Q2W
NCT01644175 · Phase 3
—75/Up to 150 mg Q2W
NCT01623115 · Phase 3
23.8%75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
n/a: no completion milestone75 mg/up to 150 mg
NCT01709500 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
12.8%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
28.1%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
16.7%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
21.6%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
9.8%150 mg Q2W
NCT02326220 · Phase 3
25.5%75 /up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644188 · Phase 3
15.4%75/Up to 150 mg Q2W
NCT01644474 · Phase 3
—75/Up150 mg Q2W
NCT01644474 · Phase 3
0%150 mg SC Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
8.2%Q2W
NCT03510884 · Phase 3
5.8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
3.7%Q4W
NCT03510884 · Phase 3
22%75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
—Alirocumab
NCT01663402 · Phase 3
15.5%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
0%
NCT02938949 · Phase 4 · registry result, not featured evidence
9.6%
NCT02984982 · Phase 4 · registry result, not featured evidence
11.2%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
12%
NCT02476006 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
5.7%New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
6.6%75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
3.8%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
0%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
8.7%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
15.3%150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
23.8%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
9.6%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
10.3%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
—75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
8.3%75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
22.4%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
24.1%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
19.3%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
19.1%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
0%300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
41.3%
NCT01576484 · Phase 2 · registry result, not featured evidence
2.9%u
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 46 more results
—Part 1 - Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.2%Part 1- Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
4.7%
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
7.7%
NCT03399370 · Phase 3
2%
NCT05192941 · Phase 4 · registry result, not featured evidence
2.9%Inclisiran - Inclisiran
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Core Part
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Extension
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran + Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
9%Inclisiran With Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
5.7%
NCT05763875 · Phase 3 · registry result, not featured evidence
5.8%
NCT04929249 · Phase 3 · registry result, not featured evidence
100%ORION-3 Rollover
NCT03814187 · Phase 3 · registry result, not featured evidence
17.6%Phase III Inclisiran-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
18.8%Phase III Placebo-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
16.8%Inclisiran
NCT04807400 · Phase 3 · registry result, not featured evidence
15.2%Inclisiran + BS
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
8.1%Part 1 - Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 1: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
4%300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
1%200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—Inclisiran Only Arm
NCT03060577 · Phase 2 · registry result, not featured evidence
19.7%Inclisiran-only
NCT03060577 · Phase 2 · registry result, not featured evidence
—Switching Arm After Day 360 Visit
NCT03060577 · Phase 2 · registry result, not featured evidence
55.6%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
6.6%300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
4.8%300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
12.1%500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
6.3%200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
1.7%200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
8.1%100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
7.3%150 mg Q2Wt
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
4.2%150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—75 /up to 150 mg Q2W
NCT01644175 · Phase 3
6.2%75/150 mg Q2W
NCT01644175 · Phase 3
—75/Up to 150 mg Q2W
NCT01623115 · Phase 3
4%75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
3%75 mg/up to 150 mg
NCT01709500 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
5.4%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
9.6%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
5.1%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
8.1%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
4.9%150 mg Q2W
NCT02326220 · Phase 3
9.2%75 /up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644188 · Phase 3
9.6%75/Up to 150 mg Q2W
NCT01644474 · Phase 3
—75/Up150 mg Q2W
NCT01644474 · Phase 3
—150 mg SC Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
0%Q2W
NCT03510884 · Phase 3
3.8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
0%Q4W
NCT03510884 · Phase 3
3.8%75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
—Alirocumab
NCT01663402 · Phase 3
6.2%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
—
NCT02938949 · Phase 4 · registry result, not featured evidence
4.8%
NCT02984982 · Phase 4 · registry result, not featured evidence
3.6%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
4.1%
NCT02476006 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
1.5%75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
1.9%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
0%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
3.5%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
8.5%150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
18.3%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
4.9%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
2.1%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
—75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
4.9%75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
6.1%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
3.7%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
8.8%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
4.3%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
—300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
2.2%
NCT01576484 · Phase 2 · registry result, not featured evidence
—u
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 46 more results
—Part 1 - Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1- Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—
NCT03399370 · Phase 3
0.3%
NCT05192941 · Phase 4 · registry result, not featured evidence
—Inclisiran - Inclisiran
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Core Part
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Extension
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran + Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
0%Inclisiran With Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
0.6%
NCT05763875 · Phase 3 · registry result, not featured evidence
0.9%
NCT04929249 · Phase 3 · registry result, not featured evidence
0%ORION-3 Rollover
NCT03814187 · Phase 3 · registry result, not featured evidence
1.5%Phase III Inclisiran-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
1.6%Phase III Placebo-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
0.7%Inclisiran
NCT04807400 · Phase 3 · registry result, not featured evidence
1%Inclisiran + BS
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
—Part 1 - Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 1: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—Inclisiran Only Arm
NCT03060577 · Phase 2 · registry result, not featured evidence
3.1%Inclisiran-only
NCT03060577 · Phase 2 · registry result, not featured evidence
—Switching Arm After Day 360 Visit
NCT03060577 · Phase 2 · registry result, not featured evidence
—
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
Serious AEs
18.7%150 mg Q2Wt
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
—150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
13.9%150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
12.6%75 /up to 150 mg Q2W
NCT01644175 · Phase 3
—75/150 mg Q2W
NCT01644175 · Phase 3
13.7%75/Up to 150 mg Q2W
NCT01623115 · Phase 3
—75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
6%75 mg/up to 150 mg
NCT01709500 · Phase 3
11.6%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
11.3%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
9.8%150 mg Q2W
NCT02326220 · Phase 3
3.4%150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—75 /up to 150 mg Q2W
NCT01644188 · Phase 3
25.9%75/Up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644474 · Phase 3
1.9%75/Up150 mg Q2W
NCT01644474 · Phase 3
—150 mg SC Q2W
NCT03156621 · Phase 3
0%150 Q2W
NCT03156621 · Phase 3
2.2%150 Q2W
NCT03156621 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
8.2%Q2W
NCT03510884 · Phase 3
3.8%Q4W
NCT03510884 · Phase 3
8.7%Q2W
NCT03510884 · Phase 3
6.1%Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
23.3%Alirocumab
NCT01663402 · Phase 3
17.4%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
40%
NCT02938949 · Phase 4 · registry result, not featured evidence
18.4%
NCT02984982 · Phase 4 · registry result, not featured evidence
9.5%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
16.2%
NCT02476006 · Phase 3 · registry result, not featured evidence
3%New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
3%New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
10.1%75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
3.8%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
1.9%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
7.6%150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
22%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
29.2%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
26.4%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
29.4%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
12.1%150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
6.1%75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
9.5%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
9%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
17.5%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
7%75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
—75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
4.1%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
7.4%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
5.3%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
2.1%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
0%300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
16.7%PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
17.4%
NCT01576484 · Phase 2 · registry result, not featured evidence
7.5%u
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 46 more results
3.2%Part 1 - Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1- Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
22.3%
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
22.4%
NCT03399370 · Phase 3
16.4%
NCT05192941 · Phase 4 · registry result, not featured evidence
—Inclisiran - Inclisiran
NCT05888103 · Phase 3 · registry result, not featured evidence
4.9%Inclisiran - Inclisiran: Core Part
NCT05888103 · Phase 3 · registry result, not featured evidence
1%Inclisiran - Inclisiran: Extension
NCT05888103 · Phase 3 · registry result, not featured evidence
15.8%Inclisiran + Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
—Inclisiran With Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
0.6%
NCT05763875 · Phase 3 · registry result, not featured evidence
11.5%
NCT04929249 · Phase 3 · registry result, not featured evidence
15.1%ORION-3 Rollover
NCT03814187 · Phase 3 · registry result, not featured evidence
30.7%Phase III Inclisiran-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
32.6%Phase III Placebo-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
8.8%Inclisiran
NCT04807400 · Phase 3 · registry result, not featured evidence
12.8%Inclisiran + BS
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
—Part 1 - Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
5.4%Part 1: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
20.8%Part 2: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
7.1%300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
6.9%200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
3.6%100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
36.6%Inclisiran Only Arm
NCT03060577 · Phase 2 · registry result, not featured evidence
—Inclisiran-only
NCT03060577 · Phase 2 · registry result, not featured evidence
34.5%Switching Arm After Day 360 Visit
NCT03060577 · Phase 2 · registry result, not featured evidence
25%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
14.8%300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
18%300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
12.3%500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
12.9%200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
18.3%200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
21.3%100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
150 mg Q2Wt
nasopharyngitis 13.5% (placebo 13.1%)
upper respiratory tract infection 7.4% (placebo 8.6%)
injection site reaction 5.9% (placebo 4.2%)
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 60 more results
150 Q2W
nasopharyngitis 13.9% (placebo 11.4%)
influenza 12.5% (placebo 2.9%)
injection site reaction 8.3% (placebo 5.7%)
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
75 /up to 150 mg Q2W
upper respiratory tract infection 7.7% (placebo 10.3%)
nasopharyngitis 7.2% (placebo 4.7%)
urinary tract infection 6.3% (placebo 3.7%)
NCT01644175 · Phase 3
75/Up to 150 mg Q2W
injection site reaction 12.4% (placebo 11%)
nasopharyngitis 11.2% (placebo 7.4%)
upper respiratory tract infection 6.8% (placebo 8.6%)
NCT01623115 · Phase 3
75 mg/up to 150 mg
influenza 14.4% (placebo 7.4%)
injection site reaction 10.8% (placebo 7.4%)
nasopharyngitis 10.8% (placebo 19.8%)
NCT01709500 · Phase 3
300 mg Q4W/Up 150 mg Q2W
injection site reaction 16.2% (placebo 7%)
upper respiratory tract infection 9% (placebo 7.9%)
nasopharyngitis 8.5% (placebo 7.9%)
NCT01926782 · Phase 3
75 mg Q2W/Up 150 mg Q2W
injection site reaction 8.7% (placebo 7%)
nasopharyngitis 8.7% (placebo 7.9%)
upper respiratory tract infection 7% (placebo 7.9%)
NCT01926782 · Phase 3
150 mg Q2W
fatigue 14.6% (placebo 9.5%)
myalgia 12.2% (placebo 4.8%)
diarrhoea 9.8% (placebo 0%)
NCT02326220 · Phase 3
150 mg Q2W
anaemia 6.9% (placebo 0%)
nasopharyngitis 3.4% (placebo 9.5%)
arthralgia 0% (placebo 9.5%)
NCT02326220 · Phase 3
75/Up to 150 mg Q2W
accidental overdose 9.8%
upper respiratory tract infection 8.8%
hypertension 6.5%
NCT01644188 · Phase 3
75/Up150 mg Q2W
nasopharyngitis 23.1%
diarrhoea 11.5%
influenza 11.5%
NCT01644474 · Phase 3
150 Q2W
diarrhoea 6.7% (placebo 0%)
headache 4.4% (placebo 8.3%)
nasopharyngitis 4.4% (placebo 0%)
NCT03156621 · Phase 3
150 Q2W
nasopharyngitis 6.7% (placebo 0%)
diarrhoea 2.2% (placebo 0%)
headache 2.2% (placebo 8.3%)
NCT03156621 · Phase 3
Q2W
nasopharyngitis 14.3% (placebo 8%)
headache 6.1% (placebo 8%)
injection site reaction 6.1% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 7.7% (placebo 8%)
upper respiratory tract infection 5.8% (placebo 12%)
injection site reaction 3.8% (placebo 0%)
NCT03510884 · Phase 3
Q2W
headache 10.9% (placebo 8%)
oropharyngeal pain 8.7% (placebo 0%)
injection site reaction 6.5% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 14.3% (placebo 8%)
covid-19 8.2% (placebo 0%)
nasopharyngitis 6.1% (placebo 8%)
NCT03510884 · Phase 3
Q2W
low density lipoprotein decreased 8% (placebo 0%)
nasopharyngitis 8% (placebo 8%)
nausea 8% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 16% (placebo 8%)
covid-19 4% (placebo 0%)
injection site reaction 4% (placebo 0%)
NCT03510884 · Phase 3
nasopharyngitis 6% (placebo 5.6%)
hypertension 5.7% (placebo 6.1%)
myalgia 5.5% (placebo 5.3%)
NCT01663402 · Phase 3
75 Q2W/Up150 Q2W
nasopharyngitis 7.5% (placebo 8.2%)
headache 6.5% (placebo 7.8%)
hypertension 5.9% (placebo 6.7%)
NCT02957682 · Phase 4 · registry result, not featured evidence
nasopharyngitis 26.2%
injection site reaction 6.8%
back pain 5.8%
NCT02984982 · Phase 4 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
urinary tract infection 5.5%
diarrhoea 5.1%
arthralgia 2.2%
NCT02642159 · Phase 4 · registry result, not featured evidence
150 mg Q2W
nasopharyngitis 22.2%
alanine aminotransferase increased 11.1%
aortic valve incompetence 11.1%
NCT03510715 · Phase 3 · registry result, not featured evidence
75 mg Q2W/up to 150 mg Q2W
aortic valve incompetence 22.2%
headache 22.2%
influenza 22.2%
NCT03510715 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.8%
myalgia 7.1%
headache 6.1%
NCT02476006 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 9.1%
arthralgia 6.1%
contusion 3%
NCT03415178 · Phase 3 · registry result, not featured evidence
urinary tract infection 6.1%
arthralgia 4.5%
contusion 1.5%
NCT03415178 · Phase 3 · registry result, not featured evidence
75 mg Q2W/up150 mg Q2W
upper respiratory tract infection 13.3%
accidental overdose 6.7%
NCT02715726 · Phase 3 · registry result, not featured evidence
150 mg Q2W
viral upper respiratory tract infection 15.1% (placebo 16.1%)
non-cardiac chest pain 7.5% (placebo 1.8%)
back pain 1.9% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 14.8% (placebo 16.1%)
pharyngitis 5.6% (placebo 0%)
back pain 0% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
150 mg Q4W/Up Q2W
viral upper respiratory tract infection 34.2% (placebo 16.1%)
fall 7% (placebo 5.4%)
back pain 5.1% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
75 or 150 mg Q2W
viral upper respiratory tract infection 14.2%
upper respiratory tract infection 10.8%
influenza 9.3%
NCT01954394 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 18.8% (placebo 5.2%)
back pain 14.6% (placebo 0%)
injection site reaction 14.6% (placebo 0%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 15.1% (placebo 5.2%)
fall 13.2% (placebo 1.7%)
diarrhoea 10.4% (placebo 3.4%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W
cough 17.6% (placebo 0%)
arthralgia 15.7% (placebo 6.9%)
osteoarthritis 15.7% (placebo 3.4%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W/Up150 mg Q2W
injection site reaction 13.8% (placebo 0%)
arthralgia 12.1% (placebo 6.9%)
headache 8.6% (placebo 6.9%)
NCT02023879 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up150 mg Q2W
headache 8.7% (placebo 6.9%)
viral upper respiratory tract infection 8.7% (placebo 5.2%)
muscle spasms 7.8% (placebo 0%)
NCT02023879 · Phase 3 · registry result, not featured evidence
75 mg/ up to 150 mg
myalgia 24.6%
nasopharyngitis 6.3%
upper respiratory tract infection 5.6%
NCT01709513 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
nasopharyngitis 4.9% (placebo 5.3%)
NCT02585778 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
dizziness 6.2% (placebo 2.9%)
nasopharyngitis 6.2% (placebo 3.9%)
diarrhoea 5.2% (placebo 1%)
NCT02289963 · Phase 3 · registry result, not featured evidence
75 mg/ Up to 150 mg Q2W
nasopharyngitis 45.5% (placebo 36.1%)
back pain 12.6% (placebo 5.6%)
injection site reaction 12.6% (placebo 4.2%)
NCT02107898 · Phase 3 · registry result, not featured evidence
75 mg/up to 150 mg + 10 mg
arthralgia 8.2%
nausea 6.1%
nasopharyngitis 4.1%
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + 20 mg
myalgia 7.4%
upper respiratory tract infection 7.4%
injection site reaction 5.6%
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + Atorvastatin 20 mg
muscle spasms 7%
back pain 5.3%
arthralgia 3.5%
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + Atorvastatin 40 mg
back pain 8.5%
nasopharyngitis 8.5%
accidental overdose 6.4%
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
300 mg Q4W
acne 20%
diarrhoea 20%
influenza like illness 20%
NCT02890992 · Phase 2 · registry result, not featured evidence
150 mg Q4W
nasopharyngitis 20%
pyogenic granuloma 20%
upper respiratory tract infection 20%
NCT02890992 · Phase 2 · registry result, not featured evidence
150 mg Q4W
abdominal discomfort 16.7%
diarrhoea 16.7%
epistaxis 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q2W
ligament sprain 11.1%
nasopharyngitis 11.1%
abdominal pain 5.6%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q2W
animal scratch 16.7%
arthropod bite 16.7%
blood follicle stimulating hormone decreased 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q4W
abdominal pain 16.7%
asthma 16.7%
depressed mood 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
50 mg Q2W
diarrhoea 33.3%
nasopharyngitis 33.3%
alcohol abuse 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
40 mg Q2W
gastroenteritis viral 30%
ear infection 10%
headache 10%
NCT02890992 · Phase 2 · registry result, not featured evidence
40 mg Q2W
pharyngitis 25%
abdominal discomfort 0%
abdominal pain 0%
NCT02890992 · Phase 2 · registry result, not featured evidence
30 mg Q2W
ear infection 25%
epistaxis 25%
fall 25%
NCT02890992 · Phase 2 · registry result, not featured evidence
viral upper respiratory tract infection 40%
acne 20%
blood bilirubin increased 20%
NCT01604824 · Phase 2 · registry result, not featured evidence
gastroenteritis 33.3%
viral upper respiratory tract infection 33.3%
abdominal discomfort 16.7%
NCT01604824 · Phase 2 · registry result, not featured evidence
headache 28.6%
acne 14.3%
angina pectoris 14.3%
NCT01604824 · Phase 2 · registry result, not featured evidence
abdominal discomfort 20%
abdominal distension 20%
acne 20%
NCT01604824 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 28.3%
nasopharyngitis 23.9%
bronchitis 21.7%
NCT01576484 · Phase 2 · registry result, not featured evidence
u
nasopharyngitis 11.6% (placebo 8.3%)
injection site reaction 9.1% (placebo 0%)
back pain 7.1% (placebo 4.2%)
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 30 more results
covid-19 18.3% (placebo 25%)
nasopharyngitis 14% (placebo 18.8%)
headache 12.9% (placebo 6.3%)
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
covid-19 44.4% (placebo 25%)
abdominal pain upper 22.2% (placebo 0%)
injection site reaction 22.2% (placebo 0%)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
headache 15.4% (placebo 0%)
influenza 15.4% (placebo 0%)
abdominal pain upper 7.7% (placebo 0%)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
nasopharyngitis 11.2% (placebo 11.2%)
diabetes mellitus 10.9% (placebo 11.7%)
hypertension 6.5% (placebo 6.7%)
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
diabetes mellitus 15.4% (placebo 13.9%)
bronchitis 5.9% (placebo 3.9%)
hypertension 5.4% (placebo 5.4%)
NCT03399370 · Phase 3
nasopharyngitis 8.2% (placebo 9.1%)
covid-19 6.1% (placebo 6.3%)
diabetes mellitus inadequate control 6.1% (placebo 5.6%)
NCT05192941 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 24.3% (placebo 16.3%)
blood glucose increased 9.7% (placebo 6.7%)
blood creatine phosphokinase increased 6.8% (placebo 5.8%)
NCT05888103 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 14% (placebo 16.3%)
blood creatine phosphokinase increased 6% (placebo 5.8%)
alanine aminotransferase increased 5% (placebo 2.9%)
NCT05888103 · Phase 3 · registry result, not featured evidence
covid-19 4.9%
injection site pain 4.9%
arthralgia 3.9%
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
headache 3.4% (placebo 0%)
nasopharyngitis 3.4% (placebo 3.4%)
urinary tract infection 1.7% (placebo 2.3%)
NCT05763875 · Phase 3 · registry result, not featured evidence
covid-19 7.7%
injection site pain 7.7%
blood creatine phosphokinase increased 4.3%
NCT04929249 · Phase 3 · registry result, not featured evidence
covid-19 18.3%
urinary tract infection 3.5%
hypertension 3.2%
NCT03814187 · Phase 3 · registry result, not featured evidence
covid-19 11.8%
diabetes mellitus inadequate control 7.5%
hypertension 7%
NCT03814187 · Phase 3 · registry result, not featured evidence
covid-19 11.9%
diabetes mellitus inadequate control 7.4%
hypertension 7.4%
NCT03814187 · Phase 3 · registry result, not featured evidence
back pain 0.4%
injection site rash 0.4%
muscle spasms 0.4%
NCT04807400 · Phase 3 · registry result, not featured evidence
dizziness 0.4%
rash 0.4%
back pain 0%
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 5.4% (placebo 0%)
pyrexia 5.4% (placebo 0%)
respiratory tract infection viral 5.4% (placebo 10.5%)
NCT03851705 · Phase 3 · registry result, not featured evidence
corona virus infection 7.5% (placebo 0%)
international normalised ratio increased 5.7% (placebo 0%)
activated partial thromboplastin time prolonged 3.8% (placebo 0%)
NCT03851705 · Phase 3 · registry result, not featured evidence
300 mg
pyrexia 18.2% (placebo 12.3%)
diabetes mellitus inadequate control 15.2% (placebo 15.8%)
diabetes mellitus 12.1% (placebo 8.8%)
NCT04666298 · Phase 2 · registry result, not featured evidence
200 mg
diabetes mellitus 11.9% (placebo 8.8%)
injection site reaction 11.9% (placebo 3.5%)
pyrexia 11.9% (placebo 12.3%)
NCT04666298 · Phase 2 · registry result, not featured evidence
100 mg
diabetes mellitus 20% (placebo 8.8%)
covid-19 14.5% (placebo 3.5%)
pyrexia 14.5% (placebo 12.3%)
NCT04666298 · Phase 2 · registry result, not featured evidence
nasopharyngitis 19.4% (placebo 6.7%)
hypertension 14.8% (placebo 2.2%)
arthralgia 14.1% (placebo 11.1%)
NCT03060577 · Phase 2 · registry result, not featured evidence
hypertension 19.5% (placebo 2.2%)
back pain 14.9% (placebo 1.1%)
nasopharyngitis 14.9% (placebo 6.7%)
NCT03060577 · Phase 2 · registry result, not featured evidence
abdominal pain upper 25%
acne 25%
angina unstable 25%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
300 mg double dose
nasopharyngitis 18% (placebo 12.9%)
musculoskeletal pain 9.8% (placebo 6.5%)
diarrhoea 8.2% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence
300 mg single dose
nasopharyngitis 14.8% (placebo 12.9%)
cough 11.5% (placebo 4.8%)
myalgia 9.8% (placebo 4.8%)
NCT02597127 · Phase 2 · registry result, not featured evidence
500 mg single dose
nasopharyngitis 13.8% (placebo 12.9%)
influenza 7.7% (placebo 3.2%)
upper respiratory tract infection 7.7% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence
200 mg double dose
diarrhoea 11.3% (placebo 3.2%)
cough 9.7% (placebo 4.8%)
arthralgia 8.1% (placebo 1.6%)
NCT02597127 · Phase 2 · registry result, not featured evidence
200 mg single dose
nasopharyngitis 13.3% (placebo 12.9%)
arthralgia 6.7% (placebo 1.6%)
back pain 6.7% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence
100 mg double dose
nasopharyngitis 13.1% (placebo 12.9%)
myalgia 11.5% (placebo 4.8%)
back pain 9.8% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 96 weeks versus 51.43 weeks.
  5. ePopulation context differs: registered conditions differ.
  6. fAssessment timepoints differ: 168 weeks versus 102.86 weeks.
  7. gTrial phases differ: Phase 3 versus Phase 2.
  8. hAssessment timepoints differ: 168 weeks versus 205.71 weeks.
  9. iAssessment timepoints differ: 36 weeks versus 51.43 weeks.
  10. jThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  11. kAssessment timepoints differ: 8 weeks versus 205.71 weeks.
  12. lTrial phases differ: Phase 2 versus Phase 3.
  13. mAssessment timepoints differ: 8 weeks versus 102.86 weeks.
  14. nAssessment timepoints differ: 208 weeks versus 47.14 weeks.
  15. oAssessment timepoints differ: 24 weeks versus 47 weeks.
  16. pAssessment timepoints differ: 96 weeks versus 47 weeks.
  17. qAssessment timepoints differ: 36 weeks versus 72.9 weeks.
  18. rAssessment timepoints differ: 18 weeks versus 51.43 weeks.
  19. sAssessment timepoints differ: 12 weeks versus 205.71 weeks.
  20. tPopulation comparability has not been reviewed for 82 of these studies.
  21. uPopulation comparability has not been reviewed for 40 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alirocumab

Total-C -33.3% (n=144) vs -1.9% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 36 more results
-35.8% (n=308) vs -0.8% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-37.4% (n=144) vs -1% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-32.9% (n=308) vs -0.1% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-37.8% (n=1530) vs -0.3% (n=780) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-38.8% (n=1530) vs 0.2% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-29.3% (n=467) vs -14.6% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-29.4% (n=467) vs -15.1% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-32.3% (n=58) vs 3% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-24.5% (n=58) vs 1.8% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-31.4% (n=322) vs 7.3% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-28.3% (n=322) vs 4.1% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-30.6% (n=166) vs 2.1% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-26.6% (n=166) vs 3.4% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-32.5% (n=37) vs -1.9% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-30% (n=76) vs -0.8% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-33.4% (n=37) vs -1% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-26.5% (n=76) vs -0.1% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-34% (n=115) vs 3% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-32.6% (n=115) vs 1.8% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-31.8% (n=126) vs -10.9% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-39.5% (n=143) vs 2% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-41.1% (n=143) vs -2.1% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-28.9% (n=48) vs -8.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-20.6% (n=53) vs -8.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-29% (n=48) vs -8.9% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-19.4% (n=53) vs -8.9% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-27.1% (n=55) vs -4% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-33.6% (n=46) vs -4% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29% (n=55) vs -6.5% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29% (n=46) vs -6.5% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29.6% (n=1058) vs -0.3% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-31.8% (n=1058) vs 1.5% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-29.6% (n=1058) vs 1.1% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-29% (n=1058) vs 1.1% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-26.5% (n=1058) vs 1.8% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-32.7% (n=126) vs -11.6% (n=122) Ezetimibe @ 12wk75/ up to 150
NCT01709513 · Phase 3 · registry result, not featured evidence
LDL-C Goal Attainment 80.7% (n=1530) vs 8.5% (n=780) placebo @ 24wk150 mg Q2W
responder rate · % of participants
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 25 more results
82.8% (n=1523) vs 8.5% (n=777) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
85.2% (n=54) vs 14.3% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
96.2% (n=53) vs 14.3% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
85.2% (n=54) vs 10.8% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
96.2% (n=53) vs 10.8% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
63.9% (n=58) vs 1.8% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
67.7% (n=57) vs 1.8% (n=56) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
72.2% (n=322) vs 2.4% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
73% (n=321) vs 2.4% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
81.4% (n=166) vs 11.3% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
82.1% (n=166) vs 11.6% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
70.3% (n=115) vs 1.8% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
72.7% (n=115) vs 1.8% (n=56) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
41.9% (n=126) vs 4.4% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
51.2% (n=123) vs 5.6% (n=118) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
96.7% (n=143) vs 10.2% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
97.9% (n=143) vs 10.6% (n=71) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
84.9% (n=48) vs 45% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
66.7% (n=53) vs 45% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
86.4% (n=48) vs 47% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
70.4% (n=51) vs 47% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
87.2% (n=55) vs 34.5% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
84.6% (n=46) vs 34.5% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
91.2% (n=52) vs 37.8% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
90% (n=46) vs 37.8% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
Fasting Triglycerides -15.6% (n=1530) vs 1.8% (n=780) placebo @ 24wk150 mg Q2W
percent change · % of baseline
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-16.7% (n=1530) vs 1.2% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
Fasting TG -13.4% (n=144) vs -1.5% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 53 more results
-15.2% (n=308) vs -0.1% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-12.3% (n=144) vs 1.8% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-13.1% (n=308) vs 0.5% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-6% (n=205) vs -5.4% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
-11.3% (n=205) vs 3% (n=106) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
-13% (n=467) vs -12.8% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-13% (n=467) vs -12.8% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-11.9% (n=52) vs -10.8% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-12.2% (n=52) vs -2.3% (n=51) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-0.6% (n=54) vs -6.4% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-18% (n=53) vs -6.4% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-9.2% (n=58) vs 1.1% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-3% (n=58) vs 2.1% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-9.6% (n=322) vs 6.3% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-8% (n=322) vs 1.7% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-10.4% (n=166) vs 0.5% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-8.1% (n=166) vs 0.6% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-9.8% (n=37) vs -1.5% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-6.7% (n=76) vs -0.1% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-18.3% (n=37) vs 1.8% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-7.3% (n=76) vs 0.5% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-13% (n=273) vs -8.8% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-14.462% (n=403) vs -14.409% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-9.965% (n=403) vs -13.585% (n=208) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-10.6% (n=115) vs 1.1% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-11.3% (n=115) vs 2.1% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-9.3% (n=126) vs -3.6% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-8% (n=126) vs -9.4% (n=122) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-13.6% (n=49) vs 1.9% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-5.7% (n=287) vs 1.9% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-8.143% (n=97) vs -3.627% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-6.999% (n=97) vs 2.113% (n=102) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-15.3% (n=143) vs 6.7% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-13.1% (n=143) vs 2.4% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-11.2% (n=48) vs -1.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-8.7% (n=53) vs -1.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-14% (n=48) vs 8.1% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-10.1% (n=53) vs 8.1% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-12% (n=55) vs -6.7% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-19.1% (n=46) vs -6.7% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-12.4% (n=55) vs -4.7% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-12.1% (n=46) vs -4.7% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
11.9% (n=49) vs 7.7% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-6.8% (n=52) vs 7.7% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-2.2% (n=49) vs 6.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-0.3% (n=52) vs 6.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-2.2% (n=49) vs 6.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-0.3% (n=52) vs 6.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
11.9% (n=49) vs 7.7% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-6.8% (n=52) vs 7.7% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-18.37% (n=93) vs -8.85% (n=89) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
LDL-C Target Achievement 78.9% (n=144) vs 9.4% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
responder rate · % of participants
NCT01926782 · Phase 3
show 7 more results
85.2% (n=308) vs 22.2% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
88.6% (n=141) vs 11.3% (n=70) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
89.5% (n=302) vs 22.5% (n=151) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
84.9% (n=37) vs 9.4% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
82.5% (n=76) vs 22.2% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
93% (n=37) vs 11.3% (n=70) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
86.4% (n=75) vs 22.5% (n=151) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
Apheresis Treatment 0.128 vs 0.806 placebo Treatments @ 18wk150 mg Q2W
absolute change · Treatments
NCT02326220 · Phase 3
show 1 more result
0.165 vs 0.774 placebo Treatments @ 18wk150 mg Q2W
NCT02326220 · Phase 3
LDL-C 30 Reduction 95.1% (n=41) vs 4.8% (n=21) placebo @ 6wk150 mg Q2W
responder rate · % of participants
NCT02326220 · Phase 3
show 10 more results
65.9% (n=41) vs 0% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
57.1% (n=45) vs 4.2% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
65.8% (n=49) vs 0.8% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
70.8% (n=52) vs 0.8% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
66.7% (n=49) vs 4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
72.5% (n=52) vs 4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
65.8% (n=49) vs 0.8% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
70.8% (n=52) vs 0.8% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
66.7% (n=49) vs 4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
72.5% (n=52) vs 4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
LDL-C 50 Reduction 63.4% (n=41) vs 0% (n=21) placebo @ 6wk150 mg Q2W
responder rate · % of participants
NCT02326220 · Phase 3
show 1 more result
43.9% (n=41) vs 0% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
W-BQ22 0.91 vs -1.43 placebo score @ 18wk150 mg Q2W
absolute change · score
NCT02326220 · Phase 3
LDL-C 15% Reduction 61.9% (n=45) vs 12.5% (n=24) placebo @ 12wk150 mg SC Q2W
responder rate · % of participants
NCT03156621 · Phase 3
ApoB/ApoA-1 -0.3 vs 0 placebo ratio @ 12wk150 mg SC Q2W
ratio to baseline · ratio
NCT03156621 · Phase 3
show 8 more results
-0.2 vs 0.1 placebo ratio @ 12wkQ2W
NCT03510884 · Phase 3
-0.3 vs 0.1 placebo ratio @ 12wkQ4W
NCT03510884 · Phase 3
-0.2 vs 0.1 placebo ratio @ 24wkQ2W
NCT03510884 · Phase 3
-0.3 vs 0.1 placebo ratio @ 24wkQ4W
NCT03510884 · Phase 3
-0.2 vs 0.1 placebo ratio @ 12wkQ2W
NCT03510884 · Phase 3
-0.3 vs 0.1 placebo ratio @ 12wkQ4W
NCT03510884 · Phase 3
-0.2 vs 0.1 placebo ratio @ 24wkQ2W
NCT03510884 · Phase 3
-0.3 vs 0.1 placebo ratio @ 24wkQ4W
NCT03510884 · Phase 3
LDL-C Less Than 130 73.3% (n=49) vs 8% (n=25) placebo @ 24wkQ2W
responder rate · % of participants
NCT03510884 · Phase 3
show 7 more results
76.3% (n=52) vs 8% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
70.6% (n=49) vs 16.4% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
72.6% (n=52) vs 16.4% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
70.6% (n=49) vs 16.4% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
72.6% (n=52) vs 16.4% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
73.3% (n=49) vs 8% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
76.3% (n=52) vs 8% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3

+ 61 further endpoints in the CSV export.

Inclisiran

Lp a Change -12.5 vs 3.2 placebo nmol/L @ 21.43wk
absolute change · nmol/L
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
-9.5 vs 5.3 placebo nmol/L @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-10.2 vs 4.4 placebo nmol/L @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-19.3 vs -5.3 Usual Care nmol/L @ 47wk
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
-3.8 vs 5.8 placebo nmol/L @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-5.6 vs 3.9 placebo nmol/L @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-5.1 vs 1.2 placebo nmol/L @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Triglycerides 6.9 vs -4.8 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 2 more results
-2.9 vs 3.5 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-3.1 vs -1.7 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
VLDL-C -12.41% (n=98) vs 5.55% (n=57) placebo @ 2wk300 mg
percent change · % of baseline
NCT04666298 · Phase 2 · registry result, not featured evidence
show 29 more results
-14.74% (n=98) vs 6.69% (n=57) placebo @ 4.29wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-17.94% (n=98) vs 9.4% (n=57) placebo @ 8.57wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-15.76% (n=98) vs 6.53% (n=57) placebo @ 12.86wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-24.05% (n=98) vs 11.56% (n=57) placebo @ 14.86wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-22.29% (n=98) vs 3.1% (n=57) placebo @ 17.14wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-18.39% (n=98) vs 3.41% (n=57) placebo @ 21.43wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-21.74% (n=98) vs -0.3% (n=57) placebo @ 25.71wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-5.56% (n=101) vs 5.55% (n=57) placebo @ 2wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-13.39% (n=101) vs 6.69% (n=57) placebo @ 4.29wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-14.02% (n=101) vs 9.4% (n=57) placebo @ 8.57wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-16.7% (n=101) vs 6.53% (n=57) placebo @ 12.86wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-12.54% (n=101) vs 11.56% (n=57) placebo @ 14.86wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-14.05% (n=101) vs 3.1% (n=57) placebo @ 17.14wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-17.49% (n=101) vs 3.41% (n=57) placebo @ 21.43wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-17.89% (n=101) vs -0.3% (n=57) placebo @ 25.71wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-2.96% (n=55) vs 5.55% (n=57) placebo @ 2wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-9.01% (n=55) vs 6.69% (n=57) placebo @ 4.29wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-10.27% (n=55) vs 9.4% (n=57) placebo @ 8.57wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-5.39% (n=55) vs 6.53% (n=57) placebo @ 12.86wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-12.1% (n=55) vs 11.56% (n=57) placebo @ 14.86wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-15.9% (n=55) vs 3.1% (n=57) placebo @ 17.14wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-10.91% (n=55) vs 3.41% (n=57) placebo @ 21.43wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-7.3% (n=55) vs -0.3% (n=57) placebo @ 25.71wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
11.8% (n=92) vs 3.3% (n=48) placebo @ 21.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0.6% (n=92) vs 10% (n=48) placebo @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
1% (n=92) vs 4.7% (n=48) placebo @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
11.9% (n=37) vs 0.6% (n=19) placebo @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
4.9% (n=37) vs 16.3% (n=19) placebo @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
12.3% (n=37) vs 10% (n=19) placebo @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
VLDL-C Change mg/dL 0.7 vs -0.9 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
-0.7 vs 0.8 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-0.7 vs -0.2 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
1.6 vs 0.6 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0.4 vs 3 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
1.5 vs 1.8 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
LDL-C Goal Attainment 84.9% (n=886) vs 31% (n=859) placebo @ 12.9wk
event count · % of participants
NCT05192941 · Phase 4 · registry result, not featured evidence · converted to % from 752 Participants as posted
Triglyceride Change mg/dL -15.32 vs -7.36 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT05888103 · Phase 3 · registry result, not featured evidence
LDL-C -67.55 mg/dL @ 47.14wk
absolute change · mg/dL
Extension (open-label)
No placebo or comparator arm
NCT05888103 · Phase 3 · registry result, not featured evidence
LDL-C Less Than 100 75.8% (n=201) vs 40.4% (n=199) Usual Care @ 47.14wk
responder rate · % of participants
Achieving LDL-C < 100 mg/dL
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
LDL-C Less Than 55 54.2% (n=201) vs 13.6% (n=199) Usual Care @ 47.14wk
responder rate · % of participants
Achieving LDL-C < 55 mg/dL
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
LDL-C -46.54% (n=174) vs 1.37% (n=87) placebo @ 21wk
percent change · % of baseline
LS Mean (Treatment Policy estimand)
NCT05763875 · Phase 3 · registry result, not featured evidence
LDL-C -64.86 vs -1.29 placebo mg/dL @ 21wk
absolute change · mg/dL
LS Mean (Treatment Policy estimand)
NCT05763875 · Phase 3 · registry result, not featured evidence
Non-HDL-C -40.45% (n=174) vs 1.88% (n=87) placebo @ 21wk
percent change · % of baseline
LS Mean (Treatment Policy estimand)
NCT05763875 · Phase 3 · registry result, not featured evidence

+ 26 further endpoints in the CSV export.

Homozygous Familial Hypercholesterolemia

Shared mechanism: PCSK9 · full Homozygous Familial Hypercholesterolemia pipeline

Alirocumab · Praluent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Homozygous Familial Hypercholesterolemiamonoclonal antibody
Partial signal

NCT03156621 · Phase 3 · completed

The trial randomized 69 participants 2:1 to triple-blinded alirocumab or matching placebo, and its primary LDL-cholesterol endpoint was met, with a statistically significant difference favoring alirocumab (p<0.0001). The record does not report a power or sample-size calculation, so the study provides meaningful but limited evidence despite its strong randomized and blinded design.

Reported efficacy

Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand): Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3) (met)

Result source: NCT03156621

Inclisiran · Leqvio

Marketed by Novartis and partners

Approved in Homozygous Familial HypercholesterolemiaRNAi (siRNA)
Partial signal

NCT04659863 · Phase 3 · completed

The first year was randomized, double-blind, and placebo-controlled, with 9 participants receiving inclisiran and 4 receiving placebo. The primary LDL-C endpoint was met, but the total sample of 13 was very small and underpowered for reliable generalization, so the findings provide limited evidence despite the favorable result.

Next expected readout: March 2028 · NCT06597006 (registry estimate)

Reported efficacy

Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) (met)

Result source: NCT04659863

Results for Homozygous Familial Hypercholesterolemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Alirocumab: 16 of 16 rows · Inclisiran: 15 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlirocumab
Rows use multiple source trials
Inclisiran
Rows use multiple source trials
Apo A1
percent change · % of baseline
5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2Wa,b,c,d,e
NCT03156621 · Phase 3
show 1 more dose
5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-1% (n=37) vs 1.6% (n=19) placebo @ 25.71wkb,c,d,e
NCT03851705 · Phase 3
Apo A1
percent change · % of baseline
No placebo or comparator arm
11.3% (n=18) @ 48wkc,d,f
NCT03510715 · Phase 3 · registry result, not featured evidence
5.5% (n=34) @ 102.86wkc,d,f
NCT03851705 · Phase 3
Apo B
percent change · % of baseline
-22.5% (n=45) vs 7.2% (n=24) placebo @ 12wk150 mg SC Q2Wa,c,d,g
NCT03156621 · Phase 3
show 1 more dose
-22.5% (n=45) vs 7.2% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-14.8% (n=9) vs 10.6% (n=4) placebo @ 51.43wkc,d,g
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Apo B
percent change · % of baseline
No placebo or comparator arm
0.9% (n=18) @ 48wkc,d,f
NCT03510715 · Phase 3 · registry result, not featured evidence
-8% (n=34) @ 102.86wkc,d,f
NCT03851705 · Phase 3
1 other source trial
-7.3% (n=13) @ 102.86wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
HDL-C
percent change · % of baseline
6.3% (n=45) vs 2.7% (n=24) placebo @ 12wk150 mg SC Q2Wa,b,c,d,e
NCT03156621 · Phase 3
show 1 more dose
6.3% (n=45) vs 2.7% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
1.5% (n=37) vs -1.9% (n=19) placebo @ 25.71wkb,c,d,e
NCT03851705 · Phase 3
HDL-C
percent change · % of baseline
No placebo or comparator arm
10.1% (n=18) @ 48wkc,d,f
NCT03510715 · Phase 3 · registry result, not featured evidence
4.1% (n=34) @ 102.86wkc,d,f
NCT03851705 · Phase 3
Lp(a
percent change · % of baseline
-19.6% (n=45) vs 8.8% (n=24) placebo @ 12wk150 mg SC Q2Wc,d,g
NCT03156621 · Phase 3
-1.7% (n=9) vs -12.1% (n=4) placebo @ 51.43wkc,d,g
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Lp(a
percent change · % of baseline
No placebo or comparator arm
-6.4% (n=18) @ 48wkc,d,f
NCT03510715 · Phase 3 · registry result, not featured evidence
-8.8% (n=13) @ 102.86wkc,d,f
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Non-HDL-C
percent change · % of baseline
-24.8% (n=45) vs 8% (n=24) placebo @ 12wk150 mg SC Q2Wa,c,d,g
NCT03156621 · Phase 3
show 1 more dose
-24.8% (n=45) vs 8% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-20.1% (n=9) vs 7.1% (n=4) placebo @ 51.43wkc,d,g
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Non-HDL-C
percent change · % of baseline
No placebo or comparator arm
5.7% (n=18) @ 48wkc,d,f
NCT03510715 · Phase 3 · registry result, not featured evidence
-5% (n=34) @ 102.86wkc,d,f
NCT03851705 · Phase 3
1 other source trial
-13% (n=13) @ 102.86wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Total Cholesterol
percent change · % of baseline
-19.8% (n=45) vs 6.6% (n=24) placebo @ 12wk150 mg SC Q2Wa,b,c,d,e
NCT03156621 · Phase 3
show 1 more dose
-19.8% (n=45) vs 6.6% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-4.9% (n=37) vs -1.4% (n=19) placebo @ 25.71wkb,c,d,e
NCT03851705 · Phase 3
Total Cholesterol
percent change · % of baseline
No placebo or comparator arm
5.5% (n=18) @ 48wkc,d,f
NCT03510715 · Phase 3 · registry result, not featured evidence
-2.9% (n=34) @ 102.86wkc,d,f
NCT03851705 · Phase 3
Dropout rate
0%150 mg SC Q2Wh
NCT03156621 · Phase 3
show 4 more results
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
8.1%Part 1 - Inclisirani
NCT03851705 · Phase 3
show 7 more results
—Part 1: Inclisiran
NCT03851705 · Phase 3
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3
—Part 2: Inclisiran
NCT03851705 · Phase 3
—Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
55.6%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Discontinued due to AEs
—150 mg SC Q2Wh
NCT03156621 · Phase 3
show 4 more results
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
—Part 1 - Inclisirani
NCT03851705 · Phase 3
show 7 more results
—Part 1: Inclisiran
NCT03851705 · Phase 3
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3
—Part 2: Inclisiran
NCT03851705 · Phase 3
—Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Serious AEs
—150 mg SC Q2Wh
NCT03156621 · Phase 3
show 4 more results
0%150 Q2W
NCT03156621 · Phase 3
2.2%150 Q2W
NCT03156621 · Phase 3
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
—Part 1 - Inclisirani
NCT03851705 · Phase 3
show 7 more results
5.4%Part 1: Inclisiran
NCT03851705 · Phase 3
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3
20.8%Part 2: Inclisiran
NCT03851705 · Phase 3
0%Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
25%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Most frequent reported AEs
150 Q2Wh
diarrhoea 6.7% (placebo 0%)
headache 4.4% (placebo 8.3%)
nasopharyngitis 4.4% (placebo 0%)
NCT03156621 · Phase 3
show 3 more results
150 Q2W
nasopharyngitis 6.7% (placebo 0%)
diarrhoea 2.2% (placebo 0%)
headache 2.2% (placebo 8.3%)
NCT03156621 · Phase 3
150 mg Q2W
nasopharyngitis 22.2%
alanine aminotransferase increased 11.1%
aortic valve incompetence 11.1%
NCT03510715 · Phase 3 · registry result, not featured evidence
75 mg Q2W/up to 150 mg Q2W
aortic valve incompetence 22.2%
headache 22.2%
influenza 22.2%
NCT03510715 · Phase 3 · registry result, not featured evidence
i
diarrhoea 5.4% (placebo 0%)
pyrexia 5.4% (placebo 0%)
respiratory tract infection viral 5.4% (placebo 10.5%)
NCT03851705 · Phase 3
show 4 more results
corona virus infection 7.5% (placebo 0%)
international normalised ratio increased 5.7% (placebo 0%)
activated partial thromboplastin time prolonged 3.8% (placebo 0%)
NCT03851705 · Phase 3
covid-19 44.4% (placebo 25%)
abdominal pain upper 22.2% (placebo 0%)
injection site reaction 22.2% (placebo 0%)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
headache 15.4% (placebo 0%)
influenza 15.4% (placebo 0%)
abdominal pain upper 7.7% (placebo 0%)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
abdominal pain upper 25%
acne 25%
angina unstable 25%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bOne study enrolled healthy volunteers and the other enrolled patients.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 12 weeks versus 25.71 weeks.
  6. fAssessment timepoints differ: 48 weeks versus 102.86 weeks.
  7. gAssessment timepoints differ: 12 weeks versus 51.43 weeks.
  8. hPopulation comparability has not been reviewed for these studies.
  9. iPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alirocumab

Fasting TG -7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
percent change · % of baseline
NCT03156621 · Phase 3
show 1 more result
-7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
ApoB/ApoA-1 -0.3 vs 0 placebo ratio @ 12wk150 mg SC Q2W
ratio to baseline · ratio
NCT03156621 · Phase 3
LDL-C -4.1% (n=18) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT03510715 · Phase 3 · registry result, not featured evidence
show 2 more results
-10.1% (n=18) @ 24wk
NCT03510715 · Phase 3 · registry result, not featured evidence
4.2% (n=18) @ 48wk
NCT03510715 · Phase 3 · registry result, not featured evidence
Fasting TG 2.8% (n=18) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT03510715 · Phase 3 · registry result, not featured evidence
show 2 more results
5.2% (n=18) @ 24wk
NCT03510715 · Phase 3 · registry result, not featured evidence
10% (n=18) @ 48wk
NCT03510715 · Phase 3 · registry result, not featured evidence

Inclisiran

Total Cholesterol Change mg/dL -15.1 vs 3.9 placebo mg/dL @ 12.86wk
absolute change · mg/dL
NCT03851705 · Phase 3
show 2 more results
0.6 vs -10.5 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3
-12.6 vs -6.8 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3
Total Cholesterol Change mg/dL -13.3 mg/dL @ 38.57wk
absolute change · mg/dL
No placebo or comparator arm
NCT03851705 · Phase 3
show 8 more results
-13 mg/dL @ 47.14wk
NCT03851705 · Phase 3
-14.4 mg/dL @ 64.29wk
NCT03851705 · Phase 3
0.1 mg/dL @ 72.86wk
NCT03851705 · Phase 3
-14.9 mg/dL @ 90wk
NCT03851705 · Phase 3
-6.9 mg/dL @ 98.57wk
NCT03851705 · Phase 3
-8.5 mg/dL @ 102.86wk
NCT03851705 · Phase 3
-77.8 mg/dL @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-118 mg/dL @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Apo B Change mg/dL -9.4 vs 10 placebo mg/dL @ 12.86wk
absolute change · mg/dL
NCT03851705 · Phase 3
show 2 more results
-1.4 vs 3.3 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3
-7.4 vs 8.4 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3
Apo B Change mg/dL -1.9 mg/dL @ 38.57wk
absolute change · mg/dL
No placebo or comparator arm
NCT03851705 · Phase 3
show 8 more results
-7.3 mg/dL @ 47.14wk
NCT03851705 · Phase 3
-6.9 mg/dL @ 64.29wk
NCT03851705 · Phase 3
1.1 mg/dL @ 72.86wk
NCT03851705 · Phase 3
-10.1 mg/dL @ 90wk
NCT03851705 · Phase 3
-10.3 mg/dL @ 98.57wk
NCT03851705 · Phase 3
-13 mg/dL @ 102.86wk
NCT03851705 · Phase 3
-95.3 mg/dL @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-86.3 mg/dL @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Non-HDL-C Change mg/dL -15.3 vs 3.8 placebo mg/dL @ 12.86wk
absolute change · mg/dL
NCT03851705 · Phase 3
show 2 more results
0.6 vs -11.6 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3
-12.7 vs -5.7 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3
Non-HDL-C Change mg/dL -17.1 mg/dL @ 38.57wk
absolute change · mg/dL
No placebo or comparator arm
NCT03851705 · Phase 3
show 8 more results
-13.9 mg/dL @ 47.14wk
NCT03851705 · Phase 3
-15.8 mg/dL @ 64.29wk
NCT03851705 · Phase 3
-2.4 mg/dL @ 72.86wk
NCT03851705 · Phase 3
-14.7 mg/dL @ 90wk
NCT03851705 · Phase 3
-7.8 mg/dL @ 98.57wk
NCT03851705 · Phase 3
-9.3 mg/dL @ 102.86wk
NCT03851705 · Phase 3
-71.8 mg/dL @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-108.5 mg/dL @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
HDL-C Change mg/dL 0.2 vs 0 placebo mg/dL @ 12.86wk
absolute change · mg/dL
NCT03851705 · Phase 3
show 2 more results
0 vs 1 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3
0 vs -1.2 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3
HDL-C Change mg/dL 0.9 mg/dL @ 47.14wk
absolute change · mg/dL
No placebo or comparator arm
NCT03851705 · Phase 3
show 7 more results
1.4 mg/dL @ 64.29wk
NCT03851705 · Phase 3
2.5 mg/dL @ 72.86wk
NCT03851705 · Phase 3
-0.2 mg/dL @ 90wk
NCT03851705 · Phase 3
1 mg/dL @ 98.57wk
NCT03851705 · Phase 3
0.8 mg/dL @ 102.86wk
NCT03851705 · Phase 3
-6 mg/dL @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-9.5 mg/dL @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Apo-A1 Change mg/dL 0.6 vs 2.6 placebo mg/dL @ 12.86wk
absolute change · mg/dL
NCT03851705 · Phase 3
show 2 more results
-1.4 vs 4 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3
-1.3 vs 1.4 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3
Apo-A1 Change mg/dL 1.2 mg/dL @ 47.14wk
absolute change · mg/dL
No placebo or comparator arm
NCT03851705 · Phase 3
show 7 more results
4.7 mg/dL @ 64.29wk
NCT03851705 · Phase 3
7.8 mg/dL @ 72.86wk
NCT03851705 · Phase 3
1.3 mg/dL @ 90wk
NCT03851705 · Phase 3
9.3 mg/dL @ 98.57wk
NCT03851705 · Phase 3
6.9 mg/dL @ 102.86wk
NCT03851705 · Phase 3
-11.5 mg/dL @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-19.8 mg/dL @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Triglycerides -21% (n=4) @ 12.86wk
percent change · % of baseline
No placebo or comparator arm
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
show 1 more result
-20.13% (n=4) @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Triglyceride Change mg/dL -35.5 mg/dL @ 12.86wk
absolute change · mg/dL
No placebo or comparator arm
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
show 1 more result
-26.3 mg/dL @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · Inclisiran's landscape